WO2023085369A1 - 角膜内皮細胞の凍結保存製剤およびその製造法 - Google Patents
角膜内皮細胞の凍結保存製剤およびその製造法 Download PDFInfo
- Publication number
- WO2023085369A1 WO2023085369A1 PCT/JP2022/041960 JP2022041960W WO2023085369A1 WO 2023085369 A1 WO2023085369 A1 WO 2023085369A1 JP 2022041960 W JP2022041960 W JP 2022041960W WO 2023085369 A1 WO2023085369 A1 WO 2023085369A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- corneal endothelial
- temperature
- frozen
- formulation
- Prior art date
Links
- 210000000399 corneal endothelial cell Anatomy 0.000 title claims abstract description 206
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 238000005138 cryopreservation Methods 0.000 title description 53
- 210000004027 cell Anatomy 0.000 claims abstract description 417
- 238000007710 freezing Methods 0.000 claims abstract description 154
- 230000008014 freezing Effects 0.000 claims abstract description 151
- 238000000034 method Methods 0.000 claims abstract description 150
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 285
- 239000000203 mixture Substances 0.000 claims description 159
- 238000009472 formulation Methods 0.000 claims description 155
- 238000003860 storage Methods 0.000 claims description 74
- 239000003112 inhibitor Substances 0.000 claims description 41
- 230000035899 viability Effects 0.000 claims description 35
- 238000010257 thawing Methods 0.000 claims description 32
- 230000003247 decreasing effect Effects 0.000 claims description 28
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 239000000306 component Substances 0.000 claims description 23
- 230000004083 survival effect Effects 0.000 claims description 22
- 239000003761 preservation solution Substances 0.000 claims description 18
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 210000000871 endothelium corneal Anatomy 0.000 claims description 16
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical group C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 claims description 13
- 238000012545 processing Methods 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000012533 medium component Substances 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 7
- 230000007774 longterm Effects 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 5
- 238000012423 maintenance Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000011435 rock Substances 0.000 claims 11
- 230000002829 reductive effect Effects 0.000 abstract description 15
- 238000001816 cooling Methods 0.000 description 58
- 239000002609 medium Substances 0.000 description 36
- 102000000568 rho-Associated Kinases Human genes 0.000 description 29
- 108010041788 rho-Associated Kinases Proteins 0.000 description 29
- 239000000243 solution Substances 0.000 description 28
- 230000003833 cell viability Effects 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 108091006905 Human Serum Albumin Proteins 0.000 description 16
- 102000008100 Human Serum Albumin Human genes 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 14
- 238000010801 machine learning Methods 0.000 description 12
- 239000012124 Opti-MEM Substances 0.000 description 11
- 239000012595 freezing medium Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 8
- 210000002159 anterior chamber Anatomy 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000004087 cornea Anatomy 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000011532 immunohistochemical staining Methods 0.000 description 7
- 238000001000 micrograph Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 108091006112 ATPases Proteins 0.000 description 5
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000002790 cross-validation Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229920001342 Bakelite® Polymers 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000004637 bakelite Substances 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- QSKQVZWVLOIIEV-NSHDSACASA-N ripasudil Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(F)=C12 QSKQVZWVLOIIEV-NSHDSACASA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012706 support-vector machine Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- VDYRZXYYQMMFJW-UHFFFAOYSA-N 2-(dimethylamino)-n-(1-oxo-2h-isoquinolin-6-yl)-2-thiophen-3-ylacetamide Chemical compound C=1C=C2C(O)=NC=CC2=CC=1NC(=O)C(N(C)C)C=1C=CSC=1 VDYRZXYYQMMFJW-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000005496 eutectics Effects 0.000 description 3
- 229960002435 fasudil Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 229950007455 ripasudil Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- JLEPZAUPTZFVIM-RHIZIOMBSA-N (3s,5s,9r,10s,13r,17r)-3-hydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,5,6,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthrene-14-carbaldehyde Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CCC33C=O)C)C3=CC[C@H]21 JLEPZAUPTZFVIM-RHIZIOMBSA-N 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- IYOZTVGMEWJPKR-YWRZDDHQSA-N C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 Chemical compound C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-YWRZDDHQSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010010996 Corneal degeneration Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000004781 bullous keratopathy Diseases 0.000 description 2
- 238000002045 capillary electrochromatography Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000015636 celiac disease-epilepsy-cerebral calcification syndrome Diseases 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 201000004180 corneal endothelial dystrophy Diseases 0.000 description 2
- 230000002338 cryopreservative effect Effects 0.000 description 2
- 210000002555 descemet membrane Anatomy 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000010583 slow cooling Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229950006594 verosudil Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- GKHIVNAUVKXIIY-UHFFFAOYSA-N 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)COC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=C4C=NNC4=CC=3)N=2)=C1 GKHIVNAUVKXIIY-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 101710099523 Dickkopf-related protein 2 Proteins 0.000 description 1
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000864647 Homo sapiens Dickkopf-related protein 2 Proteins 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910019501 NaVO3 Inorganic materials 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- OURRXQUGYQRVML-AREMUKBSSA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate Chemical compound CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 OURRXQUGYQRVML-AREMUKBSSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004045 bowman membrane Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229950009210 netarsudil Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 201000004207 posterior polymorphous corneal dystrophy Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Definitions
- the present disclosure relates to cryopreserved preparations of corneal endothelial cells, techniques for manufacturing the same, and applied techniques such as treatment using the same.
- corneal endothelial cells When the corneal endothelial cells are damaged, the cornea becomes opaque, causing severe visual impairment due to bullous keratopathy.
- the only treatment for bullous keratopathy is corneal transplantation, but there are problems such as lack of donors and rejection, and the development of new regenerative medicine treatments is desired.
- corneal endothelial cells separated from the donor cornea are proliferated in the presence of a Rho-associated coiled-coil forming kinase: Rho-associated kinase (ROCK) inhibitor, and the cells are injected into many patients to develop corneal tissue.
- Rho-associated kinase (ROCK) inhibitor Rho-associated kinase
- DMSO dimethyl sulfoxide
- frozen cell preparations used in regenerative medicine contain at least 7% DMSO, and when administered to patients, they are diluted with physiological saline immediately before administration due to concerns about the toxicity of DMSO to patients, Administration of DMSO at a high concentration to the patient is avoided by extremely slowing the administration rate during administration such as intravenous drip infusion.
- the present inventors have studied in detail the temperature conditions during cryopreservation, etc., and have reduced the DMSO concentration (e.g., less than 7%) by lowering the temperature at a slow temperature slower than -1 ° C./min. We found that the survival rate of corneal endothelial cells was kept high in a cryopreservation solution that did not contain The inventors have further found that cell viability increases when the temperature is first lowered at a slow rate and then frozen with a faster cooling rate. Therefore, the present disclosure provides a method for freezing corneal endothelial cells in a cryopreservation solution with a reduced DMSO concentration or no DMSO, and a method for producing a frozen cell preparation that can be directly administered to a patient.
- the DMSO concentration e.g., less than 7%
- the present invention provides, for example, the following items.
- (Item 1) A method for preserving corneal endothelial cells and/or corneal endothelial-like cells, comprising: A step of freezing the corneal endothelial cells and/or corneal endothelial-like cells in an unfrozen state, wherein the temperature is lowered at a rate of less than 1°C per minute when the temperature is changed from the non-freezing temperature to the freezing target temperature. and optionally maintaining said corneal endothelial cells and/or corneal endothelial-like cells in a frozen state.
- (Item 2) The method according to the preceding items, comprising the step of maintaining the corneal endothelial cells and/or corneal endothelial-like cells in a frozen state.
- (Item 3) A method according to any one of the preceding items, wherein the step of maintaining in a frozen state comprises maintaining at a frozen maintenance temperature.
- (Item 4) A method according to any one of the preceding items, wherein the cryopreservation temperature is a temperature within the range of about -80°C to about -10°C.
- (Item 5) A method according to any one of the preceding items, wherein the cryopreservation temperature is a temperature within the range of about -196°C to about -10°C.
- the cryopreservation temperature is a temperature of about -30°C or less.
- the corneal endothelial cells and/or corneal endothelial-like cells are lowered in temperature from a non-freezing temperature at a rate of about 0.1°C to about 0.9°C per minute.
- Method. (Item 8) 3. Any one of the preceding items, wherein the corneal endothelial cells and/or corneal endothelial-like cells are lowered in temperature from a non-freezing temperature at a rate of about 0.2°C to about 0.8°C per minute.
- the non-freezing temperature is a temperature within the range of about 0°C to about 37°C.
- the non-freezing temperature is a temperature within the range of about 4°C to about 23°C.
- the freezing step comprises at least one step of decreasing the temperature at a rate of less than 1°C per minute in at least a portion of the temperature range of about -20°C ⁇ 10°C. the method of.
- (Item 15) A method according to any one of the preceding items, wherein the freezing step comprises at least one step of maintaining the temperature range of about ⁇ 20° C. ⁇ 10° C. for a period of time or longer.
- the freezing step comprises at least one step of maintaining the temperature range of about ⁇ 20° C. ⁇ 10° C. for a period of time or longer.
- the corneal endothelial cells and/or corneal endothelial-like cells are preserved in a preservation solution comprising less than about 7% DMSO.
- (Item 17) The method of any one of the preceding items, wherein the corneal endothelial cells and/or corneal endothelial-like cells are preserved in a preservation solution containing about 5% or less DMSO.
- (Item 18) The method of any one of the preceding items, wherein the corneal endothelial cells and/or corneal endothelial-like cells are preserved in a preservation solution containing about 2% or less DMSO.
- (Item 19) The method according to any one of the preceding items, wherein the corneal endothelial cells and/or corneal endothelial-like cells are preserved in a DMSO-free preservation solution.
- the freezing step comprises freezing the corneal endothelial cells and/or corneal endothelial-like cells in the presence of a ROCK inhibitor.
- said freezing step comprising decreasing the temperature at a first rate to a first target temperature and decreasing the temperature from the first target temperature to a second target temperature at a second rate; A method according to any one of the preceding items, wherein one rate is less than 1°C per minute and is slower than the second rate.
- the step of freezing further comprises reducing the temperature to the first target temperature and then maintaining at the first target temperature.
- the first target temperature is a temperature within the range of about -20°C to about -5°C.
- a method for producing a frozen preparation of corneal endothelial cells and/or corneal endothelial-like cells comprising: A step of mixing the non-frozen corneal endothelial cells and/or corneal endothelial-like cells with a pharmaceutically acceptable ingredient, if necessary, and freezing to produce a frozen formulation, wherein the freezing target is changed from the non-freezing temperature a freezing step comprising at least one step of decreasing the temperature at a rate of less than 1°C per minute when changing temperature to temperature; A method comprising maintaining the frozen formulation in a frozen state.
- the method of any one of the preceding items further comprising one or more features described in the method of any or more of items 2-30.
- (Item 33) A frozen preparation of corneal endothelial cells and/or corneal endothelial-like cells produced by the method according to any one of the above items.
- (Item 34) A frozen formulation according to any one of the preceding items, comprising about 1 ⁇ 10 5 to about 3 ⁇ 10 6 corneal endothelial cells and/or corneal endothelial-like cells.
- (Item 35) The frozen formulation of any one of the preceding items, wherein the volume of the frozen formulation is from about 50 ⁇ L to about 600 ⁇ L.
- (Item 36) The frozen formulation according to any one of the above items, wherein the frozen formulation is administered in a dose of about 50 ⁇ L to about 350 ⁇ L.
- a device for preserving corneal endothelial cells and/or corneal endothelial-like cells comprising a storage/storage unit that houses a container that stores the corneal endothelial cells and/or corneal endothelial-like cells; a temperature control section for commanding to control the temperature of the corneal endothelial cells and/or corneal endothelial-like cells in the container accommodated in the storage/storage section; a temperature control unit capable of temperature control based on The temperature control unit may instruct temperature control to include at least one step of changing the temperature at a rate of less than 1°C per minute when the temperature is lowered from the non-freezing temperature to the freezing target temperature.
- a program encoding a computer-implemented method for storing corneal endothelial cells and/or corneal endothelial-like cells in a device, said device containing said corneal endothelial cells and/or corneal endothelial-like cells.
- a storage/storage unit that stores the container; a temperature control unit that commands to control the temperature of the corneal endothelial cells and/or corneal endothelial-like cells in the container stored in the storage/storage unit; a temperature adjustment unit that can adjust the temperature in based on the command of the temperature control unit,
- the program controls the temperature control unit to include at least one step of changing the temperature at a rate of less than 1°C per minute when the temperature is lowered from the non-freezing temperature to the freezing target temperature. and optionally maintaining the corneal endothelial cells and/or corneal endothelial-like cells in a frozen state.
- a recording medium storing a program encoding a computer-implemented method for storing corneal endothelial cells and/or corneal endothelial-like cells in a device, wherein the device stores the corneal endothelial cells and/or corneal endothelium.
- a storage/storage unit that stores a container that stores corneal-like cells; a temperature control unit that commands to control the temperature of the corneal endothelial cells and/or corneal endothelial-like cells in the container stored in the storage/storage unit; a temperature control unit that can control the temperature in the storage/storage unit based on a command from the temperature control unit;
- the program controls the temperature control unit to include at least one step of changing the temperature at a rate of less than 1°C per minute when the temperature is lowered from the non-freezing temperature to the freezing target temperature. and optionally maintaining the corneal endothelial cells and/or corneal endothelial-like cells in a frozen state.
- (Item 40) A frozen formulation comprising less than 7% DMSO and corneal endothelial cells and/or corneal endothelial-like cells.
- (Item 41) A frozen formulation that can be administered directly to the eye after thawing, comprising less than 7% DMSO and corneal endothelial cells and/or corneal endothelial-like cells.
- (Item 42) A frozen formulation comprising less than 7% DMSO and corneal endothelial cells and/or corneal endothelial-like cells frozen in a slow freeze state.
- (Item 43) A frozen formulation comprising less than 7% DMSO and corneal endothelial cells and/or corneal endothelial-like cells and saline components in a frozen state.
- (Item 44) A frozen preparation containing less than 7% DMSO, corneal endothelial cells and/or corneal endothelial-like cells, and medium components in a frozen state.
- (Item 45) A post-thaw long-term stable frozen cell preparation comprising less than 7% DMSO and corneal endothelial cells and/or corneal endothelial-like cells.
- (Item 46) A frozen formulation according to any one of the preceding items comprising no more than about 5% DMSO.
- (Item 47) A frozen formulation according to any one of the preceding items comprising no more than about 2% DMSO.
- (Item 48) A frozen formulation according to any one of the preceding items, which does not contain DMSO.
- (Item 49) A frozen formulation according to any one of the preceding items, further comprising a ROCK inhibitor.
- (Item 51) A frozen preparation containing a ROCK inhibitor and corneal endothelial cells and/or corneal endothelial-like cells in a frozen state.
- (Item 52) A frozen preparation containing a ROCK inhibitor, corneal endothelial cells and/or corneal endothelial-like cells, and a physiological saline component in a frozen state.
- (Item 53) A frozen preparation containing a ROCK inhibitor, corneal endothelial cells and/or corneal endothelial-like cells, and medium components in a frozen state.
- (Item 54) A post-thaw long-term stable frozen cell formulation, said formulation comprising corneal endothelial cells and/or corneal endothelial-like cells and a ROCK inhibitor.
- (Item 55) A formulation according to any one of the preceding items, wherein the viability of said corneal endothelial cells and/or corneal endothelial-like cells is at least 80% viability at room temperature for at least 6 hours after thawing.
- (Item 56) A frozen preparation that does not inhibit engraftment and in vivo survival of corneal endothelial cells and/or corneal endothelial-like cells administered after thawing, said preparation containing corneal endothelial cells and/or corneal endothelial-like cells and a ROCK inhibitor. and frozen in a slow-freezing state.
- (Item 57) A frozen formulation comprising less than 7% DMSO, a ROCK inhibitor, and corneal endothelial cells and/or corneal endothelial-like cells frozen in a slow freezing state.
- (Item 58) A formulation according to any one of the preceding items, wherein the ROCK inhibitor is Y-27632.
- (Item 60) A formulation according to any one of the preceding items comprising no more than about 5% DMSO.
- (Item 62) A formulation according to any one of the preceding items, which does not contain DMSO.
- (Item 64) A formulation according to any one of the preceding items, wherein the formulation has been frozen by decreasing the temperature from the non-freezing temperature at a rate of less than 1°C per minute.
- (Item 65) A formulation according to any one of the above items, characterized in that the corneal endothelial cells and/or corneal endothelial-like cells are used for cell injection therapy.
- (Item 66) Formulation according to any one of the preceding items, characterized in that the frozen formulation is administered without further processing or culturing after thawing.
- (Item 67) The formulation according to any one of the preceding items, comprising about 1 ⁇ 10 5 to about 3 ⁇ 10 6 corneal endothelial cells and/or corneal endothelial-like cells.
- (Item 69) The formulation according to any one of the preceding items, wherein the formulation is administered from about 50 ⁇ L to about 350 ⁇ L per administration.
- (Item 70) A frozen formulation kit comprising: a container containing a frozen formulation containing corneal endothelial cells and/or corneal endothelial-like cells in a frozen state; and a container containing the container while maintaining the frozen state.
- (Item 71) The frozen formulation kit according to item 70, wherein the frozen formulation is the formulation according to any one of the above items.
- (Item 72) A frozen formulation kit comprising the formulation according to any one of the above items, a container for containing the formulation, and a container for containing the container while maintaining the formulation in a frozen state.
- a frozen formulation kit comprising a container and a container that houses the container, A kit, wherein the container is used to contain the formulation according to any one of the above items, and the container is used to keep the formulation in a frozen state.
- a frozen formulation kit comprising: a container containing a frozen formulation containing a ROCK inhibitor and corneal endothelial cells and/or corneal endothelial-like cells in a frozen state; and a container containing the container while maintaining the frozen state.
- (Item 75) Use of a kit comprising a container and a receptacle containing the container, Use wherein the container is used to contain the formulation according to any one of the preceding items, and the container is used to keep the formulation in a frozen state.
- (Item 76) A method of transporting and/or storing a formulation according to any one of the above items, placing the formulation in a container of a kit comprising a container and a receptacle housing the container; maintaining the formulation in the kit in a frozen state; method including.
- a method for performing corneal endothelial cell injection therapy comprising: providing corneal endothelial cells and/or corneal endothelial-like cells suitable for said cell injection therapy; a freezing step comprising at least one step of lowering the temperature of said corneal endothelial cells and/or corneal endothelial-like cells from a non-freezing temperature at a rate of less than 1°C per minute; maintaining said corneal endothelial cells and/or corneal endothelial-like cells in a frozen state and optionally transporting them to said infusion therapy; A method comprising the steps of thawing said corneal endothelial cells and/or corneal endothelial-like cells and administering said corneal endothelial cells and/or corneal endothelial-like cells to a subject.
- (Item 1A) A method of preserving corneal endothelial cells and/or corneal endothelial-like cells, the method comprising: freezing the corneal endothelial cells and/or corneal endothelial-like cells in an unfrozen state, comprising decreasing the temperature at a first rate to a first target temperature; freezing, comprising decreasing the temperature at a second rate to a target temperature; and optionally maintaining the corneal endothelial cells and/or corneal endothelial-like cells in a frozen state, wherein the first The method, wherein the rate is less than 1°C per minute and is slower than the second rate. (Item 2A) 3.
- the step of freezing further comprises reducing the temperature to the first target temperature and then maintaining at the first target temperature.
- the first target temperature is a temperature within the range of about -20°C to about -5°C.
- the first target temperature is a temperature within the range of about -15°C to about -10°C.
- the second target temperature is a temperature of about -20°C or less.
- the present disclosure provides a corneal cell frozen preparation that can be directly administered to the eye after thawing.
- corneal endothelial cells can be provided all over Japan and overseas.
- FIG. 1 shows an outline of Example 1.
- FIG. 2 shows a photograph of the culture form of cells used in Example 1.
- FIG. 3 shows a graph comparing the viability of cells after thawing in cryopreservation solutions with different DMSO concentrations when 4% human serum albumin and 10% glycerin are used as base components.
- FIG. 4 shows a graph comparing the viability of cells after thawing in cryopreservation solutions with different DMSO concentrations when 4% human serum albumin and 10% polyethylene glycol are used as base components.
- FIG. 5 presents data comparing post-thaw viability of cells frozen from 23° C. at cooling rates of ⁇ 1° C./min, ⁇ 0.7° C./min or ⁇ 0.5° C./min.
- FIG. 6 shows data comparing the cell densities after freezing and storing at a cooling rate of 4° C. to -1° C./min or -0.5° C./min and 7 days after seeding after storage.
- FIG. 7 shows an outline of the second embodiment.
- FIG. 8 shows phase-contrast microscopic images of cells cultured in media supplemented with 10% or 5% DMSO.
- FIG. 9 shows phase-contrast microscopic images of cells cultured in media containing 2% DMSO and without DMSO.
- FIG. 10 is a graph showing the results of recovering cells after reseeding and examining viability.
- FIG. 11 shows an outline of the third embodiment.
- Figure 12 shows that cells frozen in Cryostor CS10 containing 10% DMSO were left at room temperature for 0 hour, 30 minutes, 1 hour, 3 hours, 6 hours, or 24 hours, and then replated in T25 culture flasks. A phase-contrast microscope image of the cultured state of cells taken after a period of time is shown.
- Figure 13 shows cells frozen in Cryostor CS5 containing 5% DMSO, left at room temperature for 0, 30, 1, 3, 6, or 24 hours and then replated into T25 culture flasks. A phase-contrast microscope image of the cultured state of cells taken after a period of time is shown.
- FIG. 14 shows cells frozen in Cryostor CS2 containing 2% DMSO were left at room temperature for 0, 30, 1, 3, 6, or 24 hours and then replated into T25 culture flasks. A phase-contrast microscope image of the cultured state of cells taken after a period of time is shown.
- FIG. 15 shows a graph showing the results of recovering cells after reseeding and examining viability. CS10, CS5, and CS2 are shown from the left of each group.
- FIG. 17 shows photomicrographs of cells cultured for 2 days after storage in a cold box.
- FIG. 18 shows a photograph of a cell-injected rabbit eye after storage in a cold box.
- FIG. 19 shows photographs of CD166 immunohistochemical staining of corneal endothelium one day after cell injection.
- FIG. 20 shows photographs of immunohistochemical staining of ZO-1 and Na/K ATPase one day after cell injection.
- FIG. 21 shows photographs of immunohistochemical staining of CD166, ZO-1 and Na/K ATPase in the corneal endothelium 5 days after cell injection.
- FIG. 22 shows an overview of cryopreservation in the cryopreservation solution of known components of Example 6. Fig.
- FIG. 23 shows -1°C/min, -0.7°C/min, and -0.5°C/min in cryopreservation solutions with different DMSO concentrations when 4% human serum albumin and 10% glycerol are used as base components. , or frozen at a cooling rate of ⁇ 0.2° C. and a graph comparing cell viability after thawing.
- 24 shows an overview of cryopreservation in the commercially available cryopreservation solution of Example 6.
- FIG. FIG. 25 shows post-thaw viability and recovery of cells frozen at a cooling rate of 4° C. to ⁇ 0.7° C./min in a commercial cryopreservation medium.
- FIG. 26 shows data comparing post-thaw viability of cells frozen from 4° C.
- FIG. 27 shows data comparing post-thaw viability of cells frozen from 4° C. at cooling rates of ⁇ 0.5° C./min or ⁇ 0.2° C./min in commercial cryopreservation media.
- 28 shows cell viability of cells preserved in Example 7.
- FIG. 29 shows the change in temperature when cooled to -80°C at -0.5°C/min.
- FIG. 30 shows the change in temperature when cooled to -10°C at -0.5°C/min, maintained at -10°C for 110 minutes, and then cooled to -80°C at -1.0°C/min. .
- FIG. 31 shows the change in temperature when cooled to -10° C. at -0.1° C./min and then cooled to -80° C. at -1.0° C./min.
- cornea endothelial cells is used in the usual sense used in the art.
- the cornea is one of the layered tissues that make up the eye, is transparent, and is positioned closest to the outside world. In humans, the cornea is said to consist of five layers in order from the outside (body surface), consisting of the corneal epithelium, Bowman's membrane, lamina intestinal, Descemet's membrane (corneal endothelial basement membrane), and corneal endothelium from the outside. Unless otherwise specified, portions other than the epithelium and endothelium may be collectively referred to as the "stroma” and are so referred to herein.
- HCEC human corneal endothelial cells
- HCEC human corneal endothelial cells
- corneal endothelial-like cells refer to cells differentiated from stem cells, such as cells differentiated from iPS cells and the like, and have substantially the same functions as corneal endothelial cells.
- Methods for differentiating stem cells, such as embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), etc., into corneal endothelial-like cells are well known in the art (McCabe et al., PLoS One. 2015 Dec 21; 10(12): e0145266; Ali et al., Invest Ophthalmol Vis Sci. 2018 May 1; 59(6): 2437-2444).
- iPS cells are seeded onto 35 mm Matrigel-coated plates (Corning) at a 1:12 dilution using Cell Dissociation Buffer (Life Technologies) on day 0 (80% confluent plates are Divide into 12 plates). iPS cells are grown in medium (mTeSR1; STEMCELL Technologies Inc.) for 4 days.
- the mTeSR1 medium was supplemented with 80% DMEM-F12 (Life Technologies), 20% KSR (Life Technologies), 1% non-essential amino acids (Life Technologies), 1 mM L-glutamine (STEMCELL Technologies, Inc.), 0 500 ng/mL human recombinant Noggin (R&D Systems, Minneapolis, Minn., USA) and 10 ⁇ M SB431542 (MilliporeSigma) in basal medium of 1 mM ⁇ -mercaptoethanol (MilliporeSigma), and 8 ng/mL ⁇ FGF (MilliporeSigma) Replace with Smad inhibitor medium.
- the Smad inhibitor medium was supplemented with 80% DMEM-F12 (Life Technologies), 20% KSR (Life Technologies), 1% non-essential amino acids (Life Technologies), 1 mM L-glutamine (STEMCELL Technologies, Inc.). , 0.1 mM ⁇ -mercaptoethanol (MilliporeSigma), and 8 ng/mL ⁇ FGF (MilliporeSigma) in basal medium with 0.1 ⁇ B27 supplement (Life Technologies), 10 ng/mL recombinant human platelet-derived growth factor-BB ( Replace with corneal medium containing PDGF-BB; PeproTech, Rocky Hill, NJ, USA) and 10 ng/mL recombinant human Dickkopf-related protein-2 (DKK-2; R&D Systems).
- differentiating CECs are transferred to new Matrigel-coated plates (35 mm) and grown in corneal medium for an additional 13 days. Differentiated CECs are harvested on day 20.
- the above example is a typical example, and those skilled in the art may apply other methods known in the art (Fukuta et al., PLoS One. 2014 Dec 2; 9(12): e112291; Hayashi et al., Nature. 2016 Mar. 17;531(7594):376-80) may also be used.
- a person skilled in the art can prepare corneal endothelial-like cells by appropriately adjusting the conditions of methods well known in the art.
- Corneal endothelial cells and “corneal endothelial-like cells” may contain a magnetic material (for example, iron).
- a magnetic material for example, iron
- corneal endothelial cells containing a magnetic substance when they are injected into the anterior chamber, they can be attracted to the inner side of the cornea (for example, Descemet's membrane) by magnetic force to promote adhesion (Patel et al., Invest Ophthalmol Vis Sci. 2009 May; 50(5): 2123-31; Mimura et al., Exp Eye Res. 2003 Jun; 76(6): 745-51; and Mimura et al., Exp Eye Res. 2005 Feb; 80(2) : 149-57).
- Magnetic substance refers to a substance that is magnetized by a magnetic field, and includes, for example, iron, cobalt, nickel, and ferrite.
- “storage” of cells means storage for a period of time in a container for any purpose (e.g., cell infusion therapy, or transportation for that purpose), without allowing the cells to proliferate, It refers to keeping cells in a container while maintaining their function. Preservation differs from “culturing” which is intended to grow cells. In addition, storage does not mean transferring cells to a container such as a syringe just before administration, nor does it mean temporarily holding cells in a container for preparation prior to administration. “Cryopreservation” means preservation in a frozen state.
- non-freezing temperature refers to a temperature at which freezing does not occur even when maintained at that temperature
- target freezing temperature refers to corneal endothelial cells and/or It refers to the target temperature for freezing corneal endothelial-like cells.
- a “freezing temperature” refers to a temperature for maintaining frozen corneal endothelial cells and/or corneal endothelial-like cells in a frozen state for a certain period of time. The cryopreservation temperature may vary as long as the object such as the target cell can be maintained in a frozen state.
- slow frozen state refers to a state frozen by a freezing process including at least one step of lowering the temperature at a rate of less than 1°C per minute.
- post-thaw long-term stability refers to maintaining at least 80% cell viability for at least 6 hours when frozen cells are maintained at room temperature after thawing.
- freeze formulation refers to a formulation that is stored in a frozen state and is in a form suitable for use after thawing, or in a form that can be prepared just before use.
- Reconstituted refers to preparing a formulation suitable for use by adding an agent or diluting with a solvent just prior to administration.
- processing refers to a change in some state or property of the cell or cell population by a specific operation when referring to a cell or cell population.
- the property of the cell population is changed. It means an operation such as adding a drug, treating with a drug, or isolating a specific cell, or an operation such as diluting or concentrating with a solvent to change the cell density.
- constant temperature refers to being within ⁇ 1°C of the set temperature.
- symptom, disorder or disease of the corneal endothelium refers to any symptom, disorder or disease occurring in the corneal endothelium.
- conditions, disorders or diseases of the corneal endothelium include Fuchs corneal endothelial dystrophy, post-corneal transplant injury, corneal endothelial inflammation, trauma, post-ophthalmic surgery injury, post-ophthalmic laser surgery injury, aging, posterior polymorphic cornea.
- Dystrophy posterior polymorphous dystrophy
- congenital hereditary corneal endothelial dystrophy CHED: congenital hereditary endothelial dystrophy
- idiopathic corneal endothelial disorder etc., but not limited thereto.
- the term "subject” refers to a subject to whom the formulation of the present disclosure is administered, and subjects include mammals (e.g., humans, mice, rats, hamsters, rabbits, cats, dogs, cows, horses, sheep , monkeys, etc.), but primates are preferred, and humans are particularly preferred.
- mammals e.g., humans, mice, rats, hamsters, rabbits, cats, dogs, cows, horses, sheep , monkeys, etc.
- primates are preferred, and humans are particularly preferred.
- kits generally refers to parts to be provided divided into two or more compartments (e.g., test agents, diagnostic agents, therapeutic agents, antibodies, labels, instructions, etc.) are provided. say the unit.
- This kit form is preferred when the purpose is to provide a composition that should not be provided in a mixed form for reasons such as stability, and is preferably used in a mixed form immediately before use.
- a kit form is preferable when providing a compound that is unstable in a solution state and needs to be reconstituted immediately before use by dissolving a lyophilized powder in a suitable solvent.
- Such kits preferably include instructions or instructions describing how to use the provided parts (e.g., test agents, diagnostic agents, therapeutic agents) or how the reagents should be handled. It is advantageous to have the
- program is used in the usual sense used in the relevant field, and is a description of processing to be performed by a computer in order, and is treated as a "product” under the Patent Law in Japan. is. All computers operate according to programs. In modern computers, programs are expressed as data in a broad sense and stored in recording media or storage devices.
- a "recording medium” is a recording medium storing a program for executing the method of the present disclosure, and any recording medium can be used as long as the program can be recorded.
- it may be an external storage device such as an internally stored ROM, HDD, magnetic disk, or flash memory such as a USB memory, but is not limited to these.
- system refers to a configuration for executing the method or program of the present disclosure, and originally refers to a system or organization for achieving a purpose, in which multiple elements are systematically configured. , affect each other, and in the field of computers, it refers to the overall configuration of hardware, software, OS, network, and the like.
- machine learning refers to technology that gives computers the ability to learn without explicit programming. It is the process by which a functional unit acquires new knowledge/skills or reconfigures existing knowledge/skills to improve its own performance. Programming computers to learn from experience reduces much of the effort required to program the details, and the field of machine learning discusses how to build computer programs that can automatically improve from experience. are doing.
- the role of data analysis and machine learning, along with the field of algorithms, is an elemental technology that forms the basis of intelligent processing, and is usually used in conjunction with other technologies. knowledge; eg medical field) is required.
- the scope of its application includes prediction (collecting data and predicting what will happen in the future), search (finding some conspicuous features from the collected data), testing/description (relationships between various elements in the data). ) and other roles.
- Machine learning is based on real-world goal achievement metrics, and machine learning users must know their real-world goals. And we need to formulate indicators that will get better when the objective is achieved.
- Machine learning is an inverse problem, an ill-posed problem for which it is unclear whether the solution has been solved.
- the behavior of learned rules is probabilistic rather than deterministic. Operational ingenuity is required on the premise that some uncontrollable part remains, and the tailor-made method of the present invention can be said to be a solution to this problem. It is also useful for machine learning users to sequentially select data and information according to real-world goals while looking at performance indicators during training and operation.
- linear regression, logistic regression, support vector machine, etc. can be used, and cross validation (also called cross validation, cross validation; Cross Validation; CV) is performed to calculate the discrimination accuracy of each model. be able to.
- machine learning linear regression, logistic regression, support vector machine, etc.
- cross-validation cross-validation
- the discrimination accuracy of each model can be calculated.
- the model with the highest accuracy can be selected.
- arbitrary machine learning can be used, and linear, logistic, support vector machine (SVM), etc. can be used as supervised machine learning.
- the corneal endothelial cells can be preserved while maintaining a high survival rate by freezing them in a preservation solution containing 10% DMSO that suppresses damage during freezing.
- a preservation solution containing 10% DMSO that suppresses damage during freezing.
- the present inventors investigated storage conditions that can maintain a high survival rate in a storage solution with reduced DMSO.
- Low DMSO concentrations (e.g., less than 7%) or DMSO-free cryopreservation have been shown to maintain high corneal endothelial cell viability by slow temperature drops, slower than 1°C/min. Found it.
- cooling rate is too slow, the extracellular water freezes first, removing the extracellular water and causing the water to flow out of the cells. Elevated concentrations of solutes within cells adversely affect cell viability. If the cooling rate is too fast, the outflow of water from the cell is suppressed, but surface crystal damage occurs in the cell, which has a detrimental effect on survival. The cooling rate in cryopreservation of cells has a great effect on cell damage. An optimal cooling rate can minimize its effects, and a cooling rate of ⁇ 1° C./min is recommended.
- a slow temperature drop slower than ⁇ 1° C./min reduced the DMSO concentration (eg, less than 7%), or reduced corneal endothelial cell viability in a DMSO-free cryopreservation medium. It was unexpected that it was kept high.
- the present disclosure provides a method of preserving corneal endothelial cells and/or corneal endothelial-like cells, comprising freezing the corneal endothelial cells and/or corneal endothelial-like cells in a non-frozen state, A freezing step comprising at least one step of decreasing the temperature at a rate of less than 1°C per minute (cooling rate slower than -1°C/min) when changing the temperature from the freezing temperature to the freezing target temperature.
- a method comprising:
- the present disclosure provides a method of producing a frozen preparation of corneal endothelial cells and/or corneal endothelial-like cells, wherein the non-frozen corneal endothelial cells and/or corneal endothelial-like cells are optionally treated with a pharmaceutical agent.
- a method may be provided comprising a freezing step comprising at least one step of allowing.
- the cooling rate of less than -1°C/min is from about 0.1°C to about 0.9°C per minute, preferably from about 0.2°C to about 0.8°C per minute. , more preferably within the range of about 0.2° C. to about 0.7° C. per minute.
- the cooling rate slower than -1°C/min is -0.9°C/min, -0.8°C/min, -0.7°C/min, -0.6°C/min, It can be -0.5°C/min, -0.4°C/min, -0.3°C/min, -0.2°C/min, or -0.1°C/min.
- the cooling rate to the freezing target temperature may or may not be constant.
- the method of the present disclosure includes at least the step of lowering the temperature at a cooling rate slower than ⁇ 1° C./min in a specific temperature range, and in the process of lowering the temperature to the freezing target temperature , may include increasing the temperature, may include decreasing the temperature at a cooling rate greater than ⁇ 1° C./min, and may include maintaining a constant temperature.
- the target freezing temperature is set appropriately, and can be, for example, a temperature within the range of about -20°C to -196°C, such as about -20°C, about -30°C, about -40°C, about -50°C, It can be about -60°C, about -70°C, about -80°C, about -90°C, about -100°C, about -150°C, about -190°C, or about -196°C.
- the method of the present disclosure may include increasing the temperature if the temperature is decreasing at an average cooling rate of less than -1°C/min in the specified temperature range. /min, or may include maintaining a constant temperature.
- the method of the present disclosure reduces the temperature at a rate faster than ⁇ 1° C./min in a particular temperature range, then maintains the constant temperature, and then increases the temperature again at a rate faster than ⁇ 1° C./min. (which may be repeated) may achieve an average cooling rate of less than -1°C/min.
- the method of the present disclosure reduces the temperature at a rate faster than ⁇ 1° C./min in a particular temperature range, then increases the temperature and then maintains the constant temperature to return to ⁇ 1° C./min.
- An average cooling rate of less than -1°C/min may be achieved by decreasing the temperature at a rate greater than 0°C/min (which may be repeated).
- the method of the present disclosure reduces the temperature at a rate faster than ⁇ 1° C./min in a specific temperature range, then increases the temperature, and then increases the temperature again at a rate faster than ⁇ 1° C./min. may be reduced (which may be repeated) to achieve an average cooling rate of less than -1°C/min.
- the specific temperature range in which the temperature is lowered at a cooling rate slower than -1°C/min can be a temperature range that includes at least the temperature at which the non-freezing state transitions to the freezing state.
- the temperature ranges are from about -80°C to about 0°C, from about -70°C to about 0°C, from about -60°C to about 0°C, from about -50°C to about 0°C, from about -40°C.
- ° C to about 0 ° C about -30 ° C to about 0 ° C, about -20 ° C to about 0 ° C, about -10 ° C to about 0 ° C, about -80 ° C to about -10 ° C, about -70 ° C to about - 10°C, about -60°C to about -10°C, about -50°C to about -10°C, about -40°C to about -10°C, about -30°C to about -10°C, or about -20°C to about It can be -10°C.
- the method of the present disclosure may further comprise maintaining the corneal endothelial cells and/or corneal endothelial-like cells in a frozen state.
- the freeze maintenance temperature is about -196°C to about -4°C, about -196°C to about -10°C, about -196°C to about -20°C, about -196°C to about -30°C.
- cryopreservation temperature may comprise maintaining at about -80°C.
- the freezing step of the disclosed method is in the range of about 0°C to about 42°C, about 0°C to about 37°C, about 4°C to about 23°C, about 4°C to about 10°C. can start from a non-freezing temperature of .
- the freezing step may start from a non-freezing temperature of 4°C.
- the methods of the present disclosure may further comprise incubating the corneal endothelial cells and/or corneal endothelial-like cells at said non-freezing temperature prior to the freezing step.
- the freezing step of the method of the present disclosure reduces the temperature at a rate of less than 1°C per minute in at least a portion or the entire temperature range of about -20°C ⁇ 10°C, or at least one step of maintaining for a period of time.
- the freezing step of the method of the present disclosure is carried out to a temperature range of about ⁇ 20° C. ⁇ 10° C. for a period of time or longer, such as 20 minutes or longer, 30 minutes or longer, 40 minutes or longer, 50 minutes or longer, 1 hour or longer. , 1 hour 30 minutes or longer, or 2 hours or longer continuously.
- the temperature range may be -20°C ⁇ 5°C.
- Non-uniform and misaligned ice crystal formation during the freezing process can lead to greater cell damage and reduced viability.
- the freezing step involves slowly lowering the temperature around the eutectic point (eg, -20°C ⁇ 10°C) of the ice crystals and the solute (eg, NaCl) in the storage solution. , or by maintaining the temperature near the eutectic point for a certain period of time, the crystals can be uniformly aligned and the damage to the cells can be reduced.
- the temperature may change at any rate.
- the present disclosure provides a method of preserving corneal endothelial cells and/or corneal endothelial-like cells, comprising freezing the corneal endothelial cells and/or corneal endothelial-like cells in an unfrozen state, comprising: a freezing step comprising at least one step of maintaining a temperature range of ⁇ 20° C. ⁇ 10° C. for a certain period of time or longer, and optionally a step of maintaining the corneal endothelial cells and/or corneal endothelial-like cells in a frozen state; Provide a method, including: The temperature may be changed at any rate outside the temperature range of -20°C ⁇ 10°C.
- the temperature is lowered below ⁇ 30° C., then the temperature is increased to a temperature range around the eutectic point ( ⁇ 20° C. ⁇ 10° C.), and the temperature is slowly decreased or constant.
- the temperature may be maintained for hours.
- those skilled in the art can appropriately adjust the time to maintain the temperature below -30°C as long as the effect of the present disclosure is achieved. minutes or less, or 20 minutes or less.
- corneal endothelial cells and/or corneal endothelial-like cells can be preserved in a preservation solution containing less than about 7%, about 5% or less, or about 2% or less DMSO. Since DMSO contained in the preservation solution may adversely affect cells, it is preferably about 5% or less, more preferably about 2% or less, and most preferably the preservation solution does not contain DMSO. . In certain embodiments, the DMSO included in the preservation solution can be about 5%. In certain embodiments, the DMSO included in the preservation solution can be about 2%.
- corneal endothelial cells and/or corneal endothelial-like cells can be frozen in the presence of a ROCK inhibitor.
- ROCK inhibitors include the following documents: U.S. Pat. No. 4,678,783, U.S. Pat. WO 2002/083175, WO 02/100833, WO 03/059913, WO 03/062227, WO 2004/009555, WO 2004/022541, WO 2004/108724, WO 2005/003101, Publication 2005/039564, WO 2005/034866, WO 2005/037197, WO 2005/037198, WO 2005/035501, WO 2005/035503, WO 2005/035506, WO 2005/080394, WO 2005 /103050, WO2006/057270, WO2007/026664, WO2014/113620, WO2019/089868, WO2014/055996, WO2019/014300, WO2019/014304, WO2018/138293 , International Publication 2018/115383, International Publication 2018/118109, International Publication 2018/102325, International Publication 2018/009622,
- Such compounds can be prepared by methods described in the respective disclosed literature.
- Specific examples include 1-(5-isoquinolinesulfonyl)homopiperazine or a salt thereof (eg, Fasudil (1-(5-isoquinolinesulfonyl)homopiperazine)), (+)-trans-4-(1-aminoethyl)- 1-(4-pyridylcarbamoyl)cyclohexane ((R)-(+)-trans-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide) or a salt thereof (for example, Y-27632 ((R )-(+)-trans-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide dihydrochloride monohydrate), etc.), and these compounds are commercially available products (Fujifilm Wako Pure Chemical Industries, Ltd., Asahi
- ROCK inhibitors that may be used include Y-27632 ((+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane), Ripasudil (4- fluoro-5- ⁇ [(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl ⁇ isoquinoline), fasudil (1-(5-isoquinolinesulfonyl)homopiperazine), verosudil (N-(1, 2-dihydro-1-oxo-6-isoquinolinyl)- ⁇ -(dimethylamino)-3-thiopheneacetamide), vermosdil (2-[3-[4-[(1H-indazol-5-yl)amino]quinazoline- 2-yl]phenoxy]-N-isopropylacetamide) and pharmaceutically acceptable salts thereof.
- the structure of vermosdil is
- the ROCK inhibitor is Ripasudil, Y-27632, Fasudil, Netarsudil, Verosudil, Vermosudil or a pharmaceutically acceptable salt thereof, more preferably Ripasudil, Y-27632 or a pharmaceutically acceptable salt thereof. acceptable salts.
- the present disclosure provides corneal endothelium produced by the above method of preserving corneal endothelial cells and/or corneal endothelial-like cells or producing a frozen preparation of corneal endothelial cells and/or corneal endothelial-like cells.
- a frozen formulation of cells and/or corneal endothelial-like cells may be provided.
- the present disclosure can provide a frozen formulation comprising less than 7% DMSO and corneal endothelial cells and/or corneal endothelial-like cells.
- the present disclosure can provide a frozen formulation comprising less than 7% DMSO and corneal endothelial cells and/or corneal endothelial-like cells frozen in a slow freezing state.
- the present disclosure can provide a frozen formulation comprising less than 7% DMSO, corneal endothelial cells and/or corneal endothelial-like cells, and saline components in a frozen state.
- the present disclosure can provide a frozen formulation comprising less than 7% DMSO, corneal endothelial cells and/or corneal endothelial-like cells, and medium components in a frozen state.
- Cell-freezing preparations used in regenerative medicine contain at least 7% DMSO. It was necessary to avoid administration of high concentrations of DMSO to patients by extremely slowing the administration rate during administration such as injection.
- the methods of the present disclosure maintained high viability when stored in stock solutions with reduced DMSO concentrations of less than 7%.
- the present disclosure has achieved frozen formulations containing previously unattainable low concentrations of DMSO of less than 7%.
- the present disclosure is a post-thaw long-term stable frozen cell formulation, wherein the formulation may be formulated comprising less than 7% DMSO and corneal endothelial cells and/or corneal endothelial-like cells.
- the present disclosure can provide a frozen formulation containing a ROCK inhibitor and corneal endothelial cells and/or corneal endothelial-like cells in a frozen state.
- the present disclosure can provide a frozen formulation comprising a ROCK inhibitor, corneal endothelial cells and/or corneal endothelial-like cells, and a saline component (eg, NaCl) in a frozen state.
- a saline component eg, NaCl
- the present disclosure can provide a frozen formulation comprising a ROCK inhibitor, corneal endothelial cells and/or corneal endothelial-like cells, and medium components in a frozen state.
- medium components include, but are not limited to, carbon sources such as glucose, amino acids, vitamins, electrolytes, phosphates, buffers, growth factors, serum, and serum albumin.
- Amino acids contained in the basal medium components are not particularly limited, and examples include L-arginine, L-cystine, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, and L-methionine.
- Vitamins contained in the basal medium components are not particularly limited, and examples include calcium D-pantothenate, choline chloride, folic acid, i-inositol, niacinamide, riboflavin, thiamine, pyridoxine, biotin, lipoic acid, vitamin B12. , adenine, thymidine and the like.
- Electrolytes contained in the medium components are not particularly limited, and examples include CaCl 2 , KCl, MgSO 4 , NaCl, NaH 2 PO 4 , NaHCO 3 , Fe(NO 3 ) 3 , FeSO 4 , CuSO 4 , MnSO 4 , Na2SiO3 , ( NH4 ) 6Mo7O24 , NaVO3 , NiCl2 , ZnSO4 and the like .
- the medium is preferably substantially free of xenogenic serum components.
- heterologous serum component herein is meant a serum component derived from an organism of a different species than the recipient. For example, when the recipient is human, sera derived from bovines and horses, such as fetal bovine serum (FBS, FCS), calf serum (CS), horse serum (HS), and the like, correspond to xenogenic serum components.
- the present disclosure provides a frozen cell formulation with long-term stability after thawing, the formulation comprising corneal endothelial cells and/or corneal endothelial-like cells and a ROCK inhibitor frozen in a slow freeze state. , can provide the formulation.
- the present disclosure is a frozen preparation that does not inhibit engraftment and in vivo survival of corneal endothelial cells and/or corneal endothelial-like cells administered after thawing, wherein the preparation contains corneal endothelial cells and/or A frozen formulation containing corneal endothelial-like cells and a ROCK inhibitor frozen in a slow freezing state can be provided.
- formulations of the present disclosure may be directly administrable to the eye after thawing.
- the number of corneal endothelial cells and/or corneal endothelial-like cells contained in the preparation can be about 1 ⁇ 10 5 to about 3 ⁇ 10 6 cells, preferably about 5 ⁇ 10 5 to about It can be 1 ⁇ 10 6 cells.
- the number of corneal endothelial cells and/or corneal endothelial-like cells contained in the formulation is, for example, about 1 ⁇ 10 5 cells, about 2 ⁇ 10 5 cells, about 3 ⁇ 10 5 cells, about 4 ⁇ 10 5 cells, about 5 ⁇ 10 5 cells, about 6 ⁇ 10 5 cells, about 7 ⁇ 10 5 cells, about 8 ⁇ 10 5 cells, about 9 ⁇ 10 5 cells , about 1 ⁇ 10 6 cells, about 2 ⁇ It can be 10 6 cells, about 3 ⁇ 10 6 cells, about 4 ⁇ 10 6 cells, or about 5 ⁇ 10 6 cells.
- the liquid volume of the formulation is about 50 ⁇ l to about 2000 ⁇ l, about 50 ⁇ l to about 1000 ⁇ l, about 50 ⁇ l to about 800 ⁇ l, about 50 ⁇ l to about 600 ⁇ l, about 50 ⁇ l to about 300 ⁇ l, about 100 ⁇ l to about 2000 ⁇ l, preferably about It may be 100 ⁇ l to about 1000 ⁇ l, more preferably about 200 ⁇ l to about 800 ⁇ l, most preferably about 300 ⁇ l to about 600 ⁇ l, but can be changed as appropriate depending on the purpose.
- Product specifications may be, for example, ⁇ about 5%, ⁇ about 10%, ⁇ about 15%, ⁇ about 20%, ⁇ about 25%, ⁇ about 50%, etc.
- the liquid volume of the formulation is at least about 50 ⁇ l, e.g. It can be about 4 ml, about 5 ml, about 6 ml, about 7 ml, about 8 ml, about 9 ml, or about 10 ml.
- the product specification when intended for injection into both eyes in cell injection therapy, the product specification may be double, triple, or quadruple the dose. Even if injection into both eyes is not intended, the product specification may be 2, 3 or 4 times the dose in case of administration failure.
- the range of the liquid amount can be appropriately combined with the above numerical values.
- the formulations of the present disclosure may be administered at about 50 ⁇ L to about 350 ⁇ L, about 250 ⁇ L to about 350 ⁇ L, about 300 ⁇ L to about 350 ⁇ L, or about 300 ⁇ L per dose.
- Formulations of the present disclosure may be administered intracamerally.
- Cell densities of formulations of the present disclosure are typically about 2 ⁇ 10 4 cells/ml or greater. While not wishing to be bound by theory, when used for cell infusion, too little cell density results in no therapeutic effect, and too high a cell density results in increased cell overlap, thereby reducing cell storage. Death may be accelerated.
- the cell density can be appropriately determined within the range of about 2 ⁇ 10 4 cells/ml to about 8 ⁇ 10 7 cells/ml, preferably about 2 ⁇ 10 4 cells/ml to about 8 ⁇ 10 7 /ml, more preferably about 2 ⁇ 10 5 to about 8 ⁇ 10 6 /ml, more preferably about 1 ⁇ 10 6 / ml to about 8 ⁇ 10 6 /ml, Most preferably from about 2 ⁇ 10 6 cells/ml to about 4 ⁇ 10 6 cells/ml.
- a person skilled in the art can determine an appropriate cell density depending on the application.
- the volume of the suspension to be stored, the optimal dosage, the optional additional ROCK inhibitor, and administration may be determined in consideration of the volume of the suspension to be stored, etc., so as to reduce the operation of adjusting the density after storage.
- the optimum dosage can be from about 1 ⁇ 10 5 to about 3 ⁇ 10 6 cells, preferably from about 5 ⁇ 10 5 to about 1 ⁇ 10 6 cells.
- a person skilled in the art can appropriately determine the number of cells contained in the preparation, the liquid volume, and the cell density so as to achieve the optimum dosage.
- corneal endothelial cells and/or corneal endothelial-like cells can be housed in a container.
- any container may be used, including plates (12, 24, 48 or 96 well plates), tubes, vials (glass vials), syringes, and dishes. but not limited to these.
- the methods of the present disclosure can preserve cells with high cell viability regardless of container type.
- the formulation may contain less than about 7%, no more than about 5%, or no more than about 2% DMSO.
- the formulation contains no more than about 5% DMSO, more preferably no more than about 2%, and most preferably no DMSO.
- the DMSO included in the formulation may be about 5%. In certain embodiments, the DMSO included in the formulation may be about 2%.
- the formulation may contain a ROCK inhibitor.
- ROCK inhibitors are described above. Since the ROCK inhibitor promotes cell adhesion, if the ROCK inhibitor is included in the formulation in advance from the time of storage, the adhesion will be promoted and storage will be adversely affected. Agents are added to the formulation immediately prior to administration. However, unexpectedly, when a ROCK inhibitor was included in the formulation in advance from the time of storage, the survival rate of the cells after storage was high, and the corneal endothelial cells and/or corneal endothelial-like cells injected into the anterior chamber engrafted to the corneal endothelium and functioned normally (Example 5).
- the corneal endothelial cell and/or corneal endothelial-like cell viability can be at least 80%, or at least 90% viability for at least 6 hours at room temperature after thawing. In some embodiments, corneal endothelial cell and/or corneal endothelial-like cell viability can be at least 90% viability for at least 3 hours at room temperature after thawing.
- the present disclosure provides a method of preserving corneal endothelial cells and/or corneal endothelial-like cells, the method comprising freezing the corneal endothelial cells and/or corneal endothelial-like cells in an unfrozen state.
- a freezing step comprising decreasing the temperature at a first rate to a first target temperature and decreasing the temperature from the first target temperature to a second target temperature at a second rate; and optionally maintaining said corneal endothelial cells and/or corneal endothelial-like cells in a frozen state, wherein the first rate is less than 1°C per minute and is faster than the second rate Late, offer a way.
- First target temperature refers to the temperature at which the supercooled state is maintained.
- the first target temperature may preferably be the temperature at which freezing starts when cooling at a faster rate than the cooling rate to the first target temperature.
- the second target temperature refers to the final target temperature obtained by further lowering the temperature from the first target temperature. We slowly reduce the temperature at a first rate under supercooling to a first target temperature, change to a second rate to initiate freezing, and reduce the temperature to a second target temperature. It was found that the cell viability was further improved by allowing The method may have one or more embodiments described in this disclosure.
- the freezing step comprises decreasing the temperature at a first rate to a first target temperature and decreasing the temperature from the first target temperature to a second target temperature at a second rate.
- the first rate can be a rate of less than 1° C. per minute and a slower rate than the second rate.
- the method may have one or more embodiments described in this disclosure.
- the freezing step may further include reducing the temperature to the first target temperature and then maintaining at the first target temperature.
- the time to maintain the first target temperature may be set as appropriate as long as the supercooled state is maintained. 40 minutes or more, about 50 minutes or more, about 60 minutes or more, about 70 minutes or more, about 80 minutes or more, about 90 minutes or more, about 100 minutes or more, about 110 minutes or more, about 120 minutes or more, about 150 minutes or more, about It can be 180 minutes or more, and can be up to about 240 minutes.
- the first target temperature may be any temperature at which the supercooled state is maintained, for example, a temperature of about -20°C to about -5°C, preferably a temperature of about -15°C to about -10°C, and more Preferably, it may be at a temperature of -13°C to -10°C.
- the second target temperature is a temperature lower than the first target temperature and can be set as appropriate.
- the first speed may be set appropriately as long as it is a slow speed, for example, a speed of about 0.9° C. or less per minute, preferably about 0.5° C. to about 0.05° C. per minute. , more preferably at a rate of about 0.3° C. to about 0.1° C. per minute.
- the second speed is faster than the first speed, and may be set as appropriate as long as the temperature is such that freezing starts when changing from the first speed to the second speed. It can be at a rate of 0.5 to about 5°C, preferably at a rate of about 1 to about 3°C per minute.
- corneal endothelial cells and/or corneal endothelial-like cells can be used for cell injection therapy.
- the formulation can be administered without further processing or culturing after thawing.
- the present disclosure provides a device for storing corneal endothelial cells and/or corneal endothelial-like cells, the device containing and storing a container containing the corneal endothelial cells and/or corneal endothelial-like cells.
- a temperature control unit for controlling the temperature of the corneal endothelial cells and/or corneal endothelial-like cells in the container stored in the storage/storage unit; a temperature control unit capable of adjusting the temperature based on a command of the unit, the temperature control unit increasing the temperature at a rate of less than 1°C per minute in decreasing the temperature from the non-freezing temperature to the freezing target temperature.
- temperature control can be commanded to include at least one step of altering, and optionally the corneal endothelial cells and/or corneal endothelial-like cells can be commanded to be maintained in a frozen state; equipment can be provided.
- the temperature control portion of the apparatus of the present disclosure when decreasing the temperature from the non-freezing temperature to the freezing target temperature, decreases the temperature to a first target temperature at a first rate and then to the first target temperature. A second rate decrease in temperature from the temperature to a second target temperature may be commanded.
- the device may have one or more embodiments described in this disclosure.
- the present disclosure is a program encoding a computer implemented method capable of preserving corneal endothelial cells and/or corneal endothelial-like cells in a device, wherein the device stores the corneal endothelial cells and/or corneal endothelial-like cells.
- a storage/storage unit that stores a container that stores the corneal endothelial-like cells, and a temperature control that instructs to control the temperature of the corneal endothelial cells and/or the corneal endothelial-like cells in the container stored in the storage/storage unit.
- the temperature control unit capable of adjusting the temperature in the storage/storage unit based on a command of the temperature control unit, the program instructing the temperature control unit to change the temperature from a non-freezing temperature to a freezing temperature.
- the temperature is controlled to include at least one step of changing the temperature at a rate of less than 1° C. per minute in lowering the temperature to the target temperature, and optionally the corneal endothelial cells and/or corneal endothelial-like
- a program may be provided that causes the cells to be maintained in a frozen state.
- the program of the present disclosure when decreasing the temperature from a non-freezing temperature to a freezing target temperature, decreases the temperature to a first target temperature at a first rate, and then from the first target temperature to a second target temperature. may be commanded to decrease the temperature at a second rate to a target temperature of .
- the program may have one or more embodiments described in this disclosure.
- the present disclosure is a recording medium storing a program encoding a computer-implemented method for preserving corneal endothelial cells and/or corneal endothelial-like cells in an apparatus, the apparatus comprising: a storage/storage unit that stores a container that stores corneal endothelial cells and/or corneal endothelial-like cells; and a temperature control unit capable of adjusting the temperature in the storage/storage unit based on the command of the temperature control unit, wherein the program instructs the temperature control unit to When the temperature is lowered from the non-freezing temperature to the target freezing temperature, the temperature is controlled so as to include at least one step of changing the temperature at a rate of less than 1 ° C. per minute, and if necessary, the corneal endothelial cells and /or a recording medium may be provided that maintains the corneal endothelial-like cells in a frozen state.
- the program stored in the recording medium of the present disclosure when lowering the temperature from the non-freezing temperature to the freezing target temperature, lowers the temperature to a first target temperature at a first rate, and then lowers the temperature to the first target temperature. from the target temperature to a second target temperature at a second rate.
- the program may have one or more embodiments described in this disclosure.
- Various functions realized by the device or program of the present disclosure may be partially or wholly realized or optimized by artificial intelligence (AI) or machine learning.
- AI artificial intelligence
- the program according to the present disclosure may be stored in a computer-readable recording medium, or may be configured as a program product.
- this "recording medium” means memory card, USB memory, SD card, flexible disk, magneto-optical disk, ROM, EPROM, EEPROM, CD-ROM, MO, DVD, and Blu-ray (registered trademark) Any “portable physical medium” such as Disc is included.
- a "program” is a data processing method written in any language or writing method, regardless of the format such as source code or binary code.
- the "program” is not necessarily limited to a single structure, but a distributed structure consisting of multiple modules or libraries, or a separate program typified by an OS (Operating System) that cooperates with Also includes those that achieve a function.
- OS Operating System
- well-known configurations and procedures can be used for the specific configuration for reading the recording medium, the reading procedure, the installation procedure after reading, and the like in each device shown in the embodiments.
- RAM random access memory
- ROM read-only memory
- hard disks fixed disk devices
- storage means such as flexible disks and optical disks
- programs, tables, databases, and web pages used for various processing and website provision.
- the specific form of distribution/integration of the devices is not limited to the one shown in the figure, and all or part of them can be functionally or physically arranged in arbitrary units according to various additions or functional loads. It can be configured by distributing and integrating In other words, the embodiments described above may be arbitrarily combined and implemented, or the embodiments may be selectively implemented.
- kits In a further aspect, the present disclosure provides a container containing a frozen preparation containing a ROCK inhibitor and corneal endothelial cells and/or corneal endothelial-like cells in a frozen state, and a container containing the container while maintaining the frozen state.
- a frozen formulation kit may be provided comprising:
- the present disclosure includes a container containing a frozen preparation containing corneal endothelial cells and/or corneal endothelial-like cells in a frozen state, and a container containing the container while maintaining the frozen state.
- Formulation kits may be provided.
- the present disclosure can provide a frozen formulation kit comprising a formulation of the present disclosure, a container containing the formulation, and a container containing the container while maintaining the formulation in a frozen state.
- the present disclosure is a frozen formulation kit comprising a container and a receptacle containing the container, the container being used to contain a formulation of the present disclosure, the receptacle comprising:
- a kit may be provided that is used to maintain the formulation in a frozen state.
- the present disclosure is the use of a kit comprising a container and a receptacle containing the container, the container being used to contain a formulation of the present disclosure, the receptacle containing the formulation. can be provided for use in maintaining a frozen state.
- the container can maintain the containing container at a temperature within the range of about -80°C to about -20°C. In some embodiments, the container can maintain the containing container at about -80°C.
- the present disclosure provides a method of transporting and/or storing a formulation of the present disclosure, comprising placing the formulation in a container of a kit comprising a container and a receptacle containing the container; maintaining the formulation in the kit in a frozen state.
- a method of performing corneal endothelial cell injection therapy comprising the steps of: providing corneal endothelial cells and/or corneal endothelial-like cells suitable for said cell injection therapy; a freezing step comprising at least one step of lowering the temperature from a non-freezing temperature at a rate of less than 1°C per minute; maintaining the corneal endothelial cells and/or corneal endothelial-like cells in a frozen state; thawing the corneal endothelial cells and/or corneal endothelial-like cells; and administering the corneal endothelial cells and/or corneal endothelial-like cells to a subject.
- a freezing step comprising at least one step of lowering the temperature from a non-freezing temperature at a rate of less than 1°C per minute
- maintaining the corneal endothelial cells and/or corneal endothelial-like cells in a frozen state thawing the corneal endothelial cells and/
- the method of the present disclosure includes decreasing the temperature at a first rate to a first target temperature and decreasing the temperature from the first target temperature to a first target temperature when decreasing the temperature from the non-freezing temperature to the freezing target temperature. Lowering the temperature at a second rate to a target temperature of 2 may be included.
- the method may have one or more embodiments described in this disclosure.
- transportation may be performed while maintaining a temperature within the range of about -80°C to about -20°C, preferably -80°C.
- Administration to a subject is preferably carried out within 6 hours after thawing. It can be done within minutes, or within 10 minutes. Administration to a subject can occur in the anterior chamber of the eye.
- Example 1 Freezing in cryopreservation solution of known components
- Glycerin and polyethylene glycol are components well known as cell cryopreservation agents, but since these components alone have low preservation effects, addition of protein components such as albumin and addition of 10% DMSO are generally performed.
- This example confirms whether HCEC can be preserved under such general conditions, and furthermore, when the cooling rate is slower than the commonly known ⁇ 1° C./min, the concentration of DMSO is low. However, the purpose is to confirm whether it can be cryopreserved.
- the temperature dropped to -80°C When the temperature dropped to -80°C, it was transferred to a bicelle processing container previously chilled at -80°C, and frozen and stored in a freezer at -80°C for 3 days. 14. After cryopreservation for 3 days, the cryotube containing the cells was thawed in a 37°C water bath for 1-2 minutes. 15. Cells were recovered in a medium that had been warmed to 37°C in advance, and the number of recovered cells and cell viability were counted by trypan blue staining.
- Example 1 An overview of Example 1 is shown in FIG. 1
- FIG. 2 shows a photograph of the cultured form of the cells used in this example. It was confirmed that the lot had no morphological abnormalities.
- Fig. 3 shows a graph comparing the viability of cells after thawing in cryopreservation solutions with different DMSO concentrations when 4% human serum albumin and 10% glycerin are used as base components.
- DMSO content was 5% or more, a high viability was maintained regardless of the cooling rate. More than 90% viability was maintained at minutes.
- BiCell is a container for storing tubes of cells to be frozen, and when placed in a deep freezer at -80°C, the temperature inside decreases at a rate of around -1°C/min. be. BiCell storage resulted in lower viability than storage at ⁇ 1° C./min in a programmed freezer.
- Fig. 4 shows a graph comparing the viability of cells after thawing, preserved in cryopreservation solutions with different DMSO concentrations when 4% human serum albumin and 10% polyethylene glycol are used as base components. Unlike the results for the cryopreservation medium containing glycerin, the effect of the cooling rate on the cell viability was also observed for the cryopreservation medium containing 5% DMSO. Compositions of 2% DMSO and below exhibited approximately 80% viability when frozen at a cooling rate of ⁇ 0.5° C./min, much higher than when frozen at a cooling rate of ⁇ 1° C./min. . These results indicate that slowing the cooling rate improves survival.
- Example 2 Examination of cryopreservation agent and freezing rate
- material ⁇ Human corneal endothelial cells after passage 4 ⁇ OptiMEM TM -I (Invitrogen 21585-070) - Triple TM Select Enzyme (10x) (Thermo Fisher Scientific A12177-01) ⁇ Red Cross Albumin 25% intravenous injection 12.5g/50mL (Japan Blood Products Organization) ⁇ 2.0ml Cryogenic Vials (Corning 430488) ⁇ Program freezer (NEPAGE PF-NP-200) ⁇ Bissel (Nippon Freezer Co., Ltd.) ⁇ iMatrix-511 (nippi 892012) ⁇ Bambanker hRM (Nippon Genetics CS-11-001) ⁇ Cryostor CS10 preformulated with 10% DMSO (Hemacare 210102) ⁇ Cryostor CS5 preformulated with 5% DMSO (Hemacare 205102) ⁇ Cryostor CS2 preformulated
- 1.2 ⁇ 10 6 cells were dispensed into 15 ml Stemfull for each cryopreservation reagent to be examined.
- cryotubes 1.2 ⁇ 10 6 cells/450 ⁇ l. 14. Freeze in a program freezer from 4°C to -80°C at -1°C/min or -0.5°C/min or -0.2°C/min. 15. When the temperature dropped to -80°C, it was transferred to a bicelle processing container previously chilled at -80°C and cryopreserved in a -80°C freezer for 3 days. 16. After cryopreservation for 3 days, the cryotube containing the cells was thawed in a 37°C water bath for 1-2 minutes. 17.
- Cells were recovered in a medium that had been warmed to 37°C in advance, and the number of recovered cells and cell viability were counted by trypan blue staining. 18. The collected cells were re-seeded in a 12-well plate at a cell density of 1000 cells/mm 2 . 19. Cultured for 2 weeks while changing the medium every 2 days. 20. On the 7th day of culture, 5 fields of view of the cells were photographed under a phase-contrast microscope (200x), and the cell density was calculated.
- phase-contrast microscope 200x
- FIG. 5 presents data comparing post-thaw viability of cells frozen from 4° C. at cooling rates of ⁇ 1° C./min, ⁇ 0.5° C./min or ⁇ 0.2° C./min.
- a cryopreservation agent containing DMSO achieved a high survival rate under all conditions of ⁇ 1° C./min, ⁇ 0.5° C./min and ⁇ 0.2° C./min.
- the DMSO-free cryopreservation improved the cell viability in inverse proportion to the cooling rate, indicating that slowing the cooling rate has the effect of increasing the cell viability.
- Fig. 6 shows the data comparing the cell densities after storage by freezing at a cooling rate of -1°C/min or -0.5°C/min from 4°C and 7 days after seeding after storage.
- Cell density was low when freezing at -1°C/min in CS2 containing 2% DMSO, Bambanker DMSO Free without DMSO, and cryoscarless DMSO Free, but at a cooling rate of -0.5°C/min High cell densities were observed when frozen. This indicated that the cooling rate also affected the cell density in culture after storage.
- Example 3 Examination of DMSO-added culture
- Method 1 Cells are collected in the same manner as in Example 2 (1-10) and stored in cryotubes using Cryostor CS2. 2. Freeze in a program freezer from 4°C to -80°C at -0.5°C/min. 3. When the temperature drops to -80°C, it is transferred to a bicelle processing container previously chilled at -80°C and frozen for 3 days in a -80°C freezer. 4. After 3 days of cryopreservation, thaw the cryotube containing the cells in a 37°C water bath for 1-2 minutes. 5.
- Cells are collected in a medium that has been warmed to 37°C in advance, and the number of collected cells and cell viability are counted by trypan blue staining. 6.
- the recovered cells are divided into four 15 ml Stemful tubes and centrifuged at 300 G ⁇ 5 min. 7. After centrifugation, the supernatant is removed, the cell density is adjusted to 1000 cells/mm 2 using media containing 10%, 5%, 2% and 0% DMSO, and the cells are reseeded on a 12-well plate. 8. Photographs of the cells are taken with a phase-contrast microscope 1 h, 3 h, 6 h, and 24 h after seeding. 9. After photographing the cells at each time, all the cells in the container including the floating cells are collected, and the cell viability is measured by trypan blue staining.
- FIG. 8 shows phase-contrast microscopic images of cells cultured in media supplemented with 10% or 5% DMSO.
- the number of cells cultured in a medium containing 10% or 5% DMSO was significantly lower than that of cells cultured in a medium without DMSO. It was shown that there were many adherent cells. Cells cultured in media without DMSO had most cells attached even 1 hour after inoculation, and all cells had attached at 3 hours, whereas DMSO 10% showed no cell attachment until 24 hours. was not accepted. Even with 5% DMSO, almost no adherent cells were observed after 1 hour, and less than half of the adherent cells were observed after 3 and 6 hours, but almost no adherent cells were observed after 24 hours. In the microscopic image of FIG. 8, white-appearing cells indicate non-adherent cells, and dark-appearing non-circular cells indicate adherent cells.
- Fig. 9 shows phase-contrast microscopic images of cells cultured in media containing 2% DMSO or not containing DMSO.
- the adhesion rate of cells cultured in medium containing 2% DMSO was not different from that of cells cultured in medium without DMSO.
- Fig. 10 is a graph showing the results of collecting cells after reseeding and examining the viability. Even the cells cultured in the medium containing 10% DMSO, which were hardly adhered in the micrograph (Fig. 8), showed no decrease in viability after 1 hour. However, since the viability decreased after that, the cells cultured in the medium containing 10% DMSO did not show a decrease in viability at 1 hour, but they were already severely damaged and therefore adhered. It is assumed that it was not possible.
- DMSO contained in the cell preparation injected into the anterior chamber is preferably 5% or less, and most preferably 2% or less or not included.
- Example 4 Examination of stability after freezing and thawing
- Method 1.
- Cells are collected in the same manner as in Example 2 (1-10) and stored in cryotubes using Cryostor CS10, CS5 and CS2, 6 cells per storage solution.
- Freeze in a program freezer from 4°C to -80°C at -0.5°C/min.
- the temperature drops to -80°C, it is transferred to a bicelle processing container previously chilled at -80°C and frozen for 3 days in a -80°C freezer.
- After 3 days of cryopreservation thaw the cryotube containing the cells in a 37°C water bath for 1-2 minutes. 5.
- Cells are immediately harvested in medium prewarmed to 37° C. for each stock solution, and cell viability is determined by trypan blue staining (0 h). The remaining 5 tubes are left at room temperature for 30 min, 1 h, 3 h, 6 h, and 24 h, then the cells are recovered in the same manner, and the cell viability is measured by trypan blue staining. 6. Cells harvested at each time are replated in a 12-well plate at a cell density of 1000 cells/mm 2 . 7. After culturing for 24 hours from the time of each reseeding, cell photographs are taken with a phase-contrast microscope.
- FIG. 12 shows cells frozen in Cryostor CS10 containing 10% DMSO were left at room temperature for 0, 30, 1, 3, 6, or 24 hours and then replated into T25 culture flasks. A phase-contrast microscope image of the cultured state of cells taken after a period of time is shown. When left at room temperature for 6 hours or longer, cell proliferation and adhesion ability were decreased.
- Figure 13 shows cells frozen in Cryostor CS5 containing 5% DMSO, left at room temperature for 0, 30, 1, 3, 6, or 24 hours and then replated into T25 culture flasks. A phase-contrast microscope image of the cultured state of cells taken after a period of time is shown. Cells left at room temperature for 6 hours showed some decrease in cell proliferation and adhesiveness, but the extent was lower compared to CS5.
- FIG. 14 shows cells frozen in Cryostor CS2 containing 2% DMSO were left at room temperature for 0, 30, 1, 3, 6, or 24 hours and then replated into T25 culture flasks. A phase-contrast microscope image of the cultured state of cells taken after a period of time is shown. No change is observed in cells left at room temperature for 6 hours.
- FIG. 15 is a graph showing the results of collecting cells after reseeding and examining the viability.
- Example 5 Cryopreservation and post-preservation corneal endothelial cell injection in VIXELL TM VIXELL TM can maintain ⁇ 75° C. ⁇ 15° C. for 18 days when filled with dry ice.
- VIXELL TM is used to store and transport corneal endothelial cells, followed by injection of corneal endothelial cells.
- Method (Method) (Cryopreservation) 1.
- the cultured corneal endothelial cells were collected and suspended in CryoStor® CS2 supplemented with 100 ⁇ M Y27632 at a cell density of 1.2 ⁇ 10 6 cells/450 ⁇ l.
- the vials were frozen from 4°C down to -80°C at a rate of -0.5°C/min.
- Stored vials were placed in BICELL TM and stored once in a deep freezer at -80°C. 4.
- Stored vials were removed and stored in VIXELL TM with dry ice for 5 days.
- the anterior segment of the eye was observed with a slit-lamp microscope at 1, 2, 3, and 5 days to confirm the presence or absence of inflammation and infection.
- 5 mg/mL of Prograf injection was diluted with 100 mL of physiological saline, and the total volume of 6 mL was injected into the posterior auricular vein. Euthanasia was performed 1 and 5 days after the operation, and immunostaining was performed.
- FIG. 16 shows the survival rate and cell recovery rate when cells stored in a cold box for 5 days were thawed.
- the survival rate was calculated as the number of viable cells/total number of cells at 5 days.
- the cell recovery rate was defined as the recovery rate when the theoretical cell number (filled cell number) was taken as 100%.
- FIG. 17 shows photomicrographs of cells cultured for 2 days after storage in a cold box. Since the cells adhered to the bottom surface of the incubator with the same shape as the non-frozen cells, it was confirmed that normal traits were maintained.
- Fig. 18 shows a photograph of a cell-injected rabbit eye after storage in a cooling box.
- the corneal transparency was maintained by engraftment of corneal endothelial cells.
- FIG. 19 shows photographs of CD166 immunohistochemical staining of the corneal endothelium one day after cell injection.
- the tissue of corneal endothelium was fixed, an antibody against CD166, which is one of the expression markers of corneal endothelial cells, was conjugated as a primary antibody, and then a fluorescence-labeled secondary antibody was conjugated to perform immunohistochemical staining. It was confirmed that the injected cells were cleanly engrafted on the monolayer, and that CD166 was strongly expressed.
- the upper row shows the central cornea, and the lower row shows the peripheral part. Since staining was performed with an antibody that binds only to human CD166, the rabbit corneal endothelium was not stained and a clear border was confirmed.
- FIG. 20 shows photographs of immunohistochemical staining of ZO-1 and Na/K ATPase one day after cell injection.
- ZO-1 and Na/K ATPase are expressed as functional molecules in corneal endothelial cells.
- FIG. 21 shows photographs of immunohistochemical staining of CD166, ZO-1 and Na/K ATPase in the corneal endothelium 5 days after cell injection.
- Example 6 Freezing at a cooling rate of -0.7 ° C. / min
- the corneal endothelium when frozen at a cooling rate of 4° C. to -0.7° C./min in a cryopreservation solution of known components similar to that in Example 1 and a commercially available preservation solution similar to that in Example 2
- the purpose is to confirm cell viability.
- FIGS 22 and 24 show an overview of this embodiment.
- FIG. 23 shows -1°C/min, -0.7°C/min, and -0.5°C/min in cryopreservation solutions with different DMSO concentrations when 4% human serum albumin and 10% glycerol are used as base components. , or frozen at a cooling rate of ⁇ 0.2° C. and a graph comparing cell viability after thawing. Cryopreservation solutions containing 10% DMSO tended to improve viability when frozen at cooling rates of -0.5°C/min and -0.2°C.
- FIG. 25 shows the survival rate and recovery rate after thawing of cells frozen at a cooling rate of 4°C to -0.7°C/min in a commercially available cryopreservation solution. Viability was calculated as the number of viable cells/total number of cells. The cell recovery rate was defined as the recovery rate when the theoretical cell number (filled cell number) was taken as 100%.
- FIG. 26 shows data comparing post-thaw viability of cells frozen from 4° C. at cooling rates of ⁇ 1° C./min or ⁇ 0.7° C./min in commercial cryopreservation media.
- FIG. 27 shows data comparing post-thaw viability of cells frozen from 4° C.
- cell viability is improved by freezing and preserving at a cooling rate of -0.7°C/min or lower.
- a cryopreservation solution containing DMSO as low as 2% and a cryopreservation solution containing no DMSO significantly improved the survival rate. Therefore, the method of the present disclosure can reduce DMSO during cryopreservation. be possible.
- Example 7 Cryopreservation in glass vial formulation
- cryopreservation was performed in glass vials. As shown below, high viability can be preserved by freezing at a slow cooling rate regardless of the container.
- Figures 29-31 show the transition of temperature.
- the rapid temperature rise of the sample is due to the latent heat seen during cooling. It was shown to be preserved with a high survival rate of over 85% when cooled to -80°C at -0.5°C/min and frozen. In addition, when HSA was added and stored under the same cooling conditions, the survival rate was further increased, exceeding 90%.
- the control group was also cooled at a slow rate to -10°C (then the temperature may be maintained at -10°C for a certain period of time) and then cooled at a rate of -1.0°C/min for storage. showed a survival rate of over 90% (Fig. 28). No abnormalities in cell shape were observed in any of the preservation groups.
- a method for freezing corneal endothelial cells in a cryopreservation solution with a reduced DMSO concentration or no DMSO and a method for producing a frozen cell preparation that can be directly administered to a patient. Since the formulation can be used for cell transplantation and the like in this way, it can be used in fields such as pharmaceuticals.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
(項目1)
角膜内皮細胞および/または角膜内皮様細胞を保存する方法であって、
非凍結状態の該角膜内皮細胞および/または角膜内皮様細胞を凍結する工程であって、非凍結温度から凍結目標温度に温度を変更する際に、1分あたり1℃未満の速度で温度を低下させる段階を少なくとも1つ含む、凍結工程、および
必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持する工程
を含む、方法。
(項目2)
角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持する工程を含む、上記項目に記載の方法。
(項目3)
前記凍結状態で維持する工程は、凍結維持温度で維持することを含む、上記項目のいずれか一項に記載の方法。
(項目4)
前記凍結維持温度が、約-80℃~約-10℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目5)
前記凍結維持温度が、約-196℃~約-10℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目6)
前記凍結維持温度が、約-30℃以下の温度である、上記項目のいずれか一項に記載の方法。
(項目7)
前記角膜内皮細胞および/または角膜内皮様細胞が、非凍結温度から1分あたり約0.1℃~約0.9℃の速度で温度を低下される、上記項目のいずれか一項に記載の方法。
(項目8)
前記角膜内皮細胞および/または角膜内皮様細胞が、非凍結温度から1分あたり約0.2℃~約0.8℃の速度で温度を低下される、上記項目のいずれか一項に記載の方法。
(項目9)
前記角膜内皮細胞および/または角膜内皮様細胞が、非凍結温度から1分あたり約0.7℃以下の速度で温度を低下される、上記項目のいずれか一項に記載の方法。
(項目10)
前記角膜内皮細胞および/または角膜内皮様細胞が、非凍結温度から1分あたり約0.2℃~約0.7℃の速度で温度を低下される、上記項目のいずれか一項に記載の方法。
(項目11)
前記非凍結温度が、約0℃~約42℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目12)
前記非凍結温度が、約0℃~約37℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目13)
前記非凍結温度が、約4℃~約23℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目14)
前記凍結工程は、約-20℃±10℃の少なくとも一部の温度範囲において、1分あたり1℃未満の速度で温度を低下させる段階を少なくとも1つ含む、上記項目のいずれか一項に記載の方法。
(項目15)
前記凍結工程は、約-20℃±10℃の温度範囲に一定時間以上維持する段階を少なくとも1つ含む、上記項目のいずれか一項に記載の方法。
(項目16)
前記角膜内皮細胞および/または角膜内皮様細胞が、約7%未満のDMSOを含む保存液中で保存される、上記項目のいずれか一項に記載の方法。
(項目17)
前記角膜内皮細胞および/または角膜内皮様細胞が、約5%以下のDMSOを含む保存液中で保存される、上記項目のいずれか一項に記載の方法。
(項目18)
前記角膜内皮細胞および/または角膜内皮様細胞が、約2%以下のDMSOを含む保存液中で保存される、上記項目のいずれか一項に記載の方法。
(項目19)
前記角膜内皮細胞および/または角膜内皮様細胞が、DMSOを含まない保存液中で保存される、上記項目のいずれか一項に記載の方法。
(項目20)
前記凍結工程は、角膜内皮細胞および/または角膜内皮様細胞がROCK阻害剤の存在下で凍結されていることを含む、上記項目のいずれか一項に記載の方法。
(項目21)
前記凍結工程が、第1の目標温度まで第1の速度で温度を低下させること、および第1の目標温度から第2の目標温度まで第2の速度で温度を低下させることを含み、該第1の速度が、1分あたり1℃未満の速度であり、該第2の速度よりも遅い、上記項目のいずれか一項に記載の方法。
(項目22)
前記凍結工程が、前記第1の目標温度まで温度を低下させた後、前記第1の目標温度で維持することをさらに含む、上記項目のいずれか一項に記載の方法。
(項目23)
前記第1の目標温度が、約-20℃~約-5℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目24)
前記第1の目標温度が、約-15℃~約-10℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目25)
前記第2の目標温度が、約-20℃以下の温度である、上記項目のいずれか一項に記載の方法。
(項目26)
前記第2の目標温度が、約-196℃~約-80℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目27)
前記第1の速度が、1分あたり約0.5℃~約0.05℃の速度である、上記項目のいずれか一項に記載の方法。
(項目28)
前記第1の速度が、1分あたり約0.3℃~約0.1℃の速度である、上記項目のいずれか一項に記載の方法。
(項目29)
前記第2の速度が、1分あたり約0.5~約5℃の速度である、上記項目のいずれか一項に記載の方法。
(項目30)
前記第2の速度が、1分あたり約1~約3℃の速度である、上記項目のいずれか一項に記載の方法。
(項目31)
角膜内皮細胞および/または角膜内皮様細胞の凍結製剤を生産する方法であって、
非凍結状態の該角膜内皮細胞および/または角膜内皮様細胞を必要に応じて薬学的に受容可能な成分と混合し、凍結して凍結製剤を生産する工程であって、非凍結温度から凍結目標温度に温度を変更する際に、1分あたり1℃未満の速度で温度を低下させる段階を少なくとも1つ含む、凍結工程、および
必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞の該凍結製剤を凍結状態で維持する工程
を含む、方法。
(項目32)
項目2~30のいずれかまたは複数の項に記載の方法に記載される1または複数の特徴をさらに含む、上記項目のいずれか一項に記載の方法。
(項目33)
上記項目のいずれか一項に記載の方法によって製造される角膜内皮細胞および/または角膜内皮様細胞の凍結製剤。
(項目34)
前記角膜内皮細胞および/または角膜内皮様細胞を約1×105~約3×106個を含む、上記項目のいずれか一項に記載の凍結製剤。
(項目35)
前記凍結製剤の体積は、約50μL~約600μLである、上記項目のいずれか一項に記載の凍結製剤。
(項目36)
前記凍結製剤は、1回あたり約50μL~約350μL投与されることを特徴とする、上記項目のいずれか一項に記載の凍結製剤。
(項目37)
角膜内皮細胞および/または角膜内皮様細胞を保存する装置であって、該装置は
該角膜内皮細胞および/または角膜内皮様細胞を収容する容器を収容する収容・保存部と、
収容・保存部において収容された容器内の角膜内皮細胞および/または角膜内皮様細胞の温度を制御するように指令する温度制御部と
該収容・保存部における温度を、該温度制御部の指令に基づいて温度調節し得る、温度調節部と
を含み、
該温度制御部は、非凍結温度から凍結目標温度に温度を低下させる際に、1分あたり1℃未満の速度で温度を変更する段階を少なくとも1つ含むように温度制御するよう指令することができ、必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持するように指令することができる、装置。
(項目38)
装置において角膜内皮細胞および/または角膜内皮様細胞を保存することができるようにコンピュータに実装させる方法をコードするプログラムであって、該装置は該角膜内皮細胞および/または角膜内皮様細胞を収容する容器を収容する収容・保存部と、収容・保存部において収容された容器内の角膜内皮細胞および/または角膜内皮様細胞の温度を制御するように指令する温度制御部と、該収容・保存部における温度を、該温度制御部の指令に基づいて温度調節し得る、温度調節部とを含み、
該プログラムは、該温度制御部に対して、非凍結温度から凍結目標温度に温度を低下させる際に、1分あたり1℃未満の速度で温度を変更する段階を少なくとも1つ含むように温度制御させ、必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持させる、プログラム。
(項目39)
装置において角膜内皮細胞および/または角膜内皮様細胞を保存することができるようにコンピュータに実装させる方法をコードするプログラムを格納した記録媒体であって、該装置は該角膜内皮細胞および/または角膜内皮様細胞を収容する容器を収容する収容・保存部と、収容・保存部において収容された容器内の角膜内皮細胞および/または角膜内皮様細胞の温度を制御するように指令する温度制御部と、該収容・保存部における温度を、該温度制御部の指令に基づいて温度調節し得る、温度調節部とを含み、
該プログラムは、該温度制御部に対して、非凍結温度から凍結目標温度に温度を低下させる際に、1分あたり1℃未満の速度で温度を変更する段階を少なくとも1つ含むように温度制御させ、必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持させる、記録媒体。
(項目40)
7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞とを含む、凍結製剤。
(項目41)
7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞とを含む、解凍後眼に直接投与可能な凍結製剤。
(項目42)
7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞とを緩慢凍結状態で凍結された状態で含む、凍結製剤。
(項目43)
7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞と生理食塩水の成分とを凍結状態で含む凍結製剤。
(項目44)
7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞と培地成分とを凍結状態で含む凍結製剤。
(項目45)
7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞とを含む解凍後長期安定性凍結細胞製剤。
(項目46)
約5%以下のDMSOを含む、上記項目のいずれか一項に記載の凍結製剤。
(項目47)
約2%以下のDMSOを含む、上記項目のいずれか一項に記載の凍結製剤。
(項目48)
DMSOを含まない、上記項目のいずれか一項に記載の凍結製剤。
(項目49)
ROCK阻害剤をさらに含む、上記項目のいずれか一項に記載の凍結製剤。
(項目50)
前記ROCK阻害剤が、Y-27632である、上記項目のいずれか一項に記載の凍結製剤。
(項目51)
ROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞とを凍結状態で含む凍結製剤。
(項目52)
ROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞と生理食塩水の成分とを凍結状態で含む凍結製剤。
(項目53)
ROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞と培地成分とを凍結状態で含む凍結製剤。
(項目54)
解凍後長期安定性凍結細胞製剤であって、該製剤は、角膜内皮細胞および/または角膜内皮様細胞とROCK阻害剤とを含む、製剤。
(項目55)
前記角膜内皮細胞および/または角膜内皮様細胞の生存率が、解凍後、室温で少なくとも6時間少なくとも80%の生存率である、上記項目のいずれか一項に記載の製剤。
(項目56)
解凍後投与された角膜内皮細胞および/または角膜内皮様細胞の生着および生体内における生存が阻害されない凍結製剤であって、該製剤は、角膜内皮細胞および/または角膜内皮様細胞とROCK阻害剤とを緩慢凍結状態で凍結された状態で含む、凍結製剤。
(項目57)
7%未満のDMSOとROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞とを緩慢凍結状態で凍結された状態で含む、凍結製剤。
(項目58)
前記ROCK阻害剤が、Y-27632である、上記項目のいずれか一項に記載の製剤。
(項目59)
約7%未満のDMSOを含む、上記項目のいずれか一項に記載の製剤。
(項目60)
約5%以下のDMSOを含む、上記項目のいずれか一項に記載の製剤。
(項目61)
約2%以下のDMSOを含む、上記項目のいずれか一項に記載の製剤。
(項目62)
DMSOを含まない、上記項目のいずれか一項に記載の製剤。
(項目63)
前記製剤は、緩慢凍結状態で凍結された状態で前記細胞を含む、上記項目のいずれか一項に記載の製剤。
(項目64)
前記製剤が、非凍結温度から1分あたり1℃未満の速度で温度を低下させて凍結されたものである、上記項目のいずれか一項に記載の製剤。
(項目65)
前記角膜内皮細胞および/または角膜内皮様細胞が、細胞注入療法に使用されることを特徴とする、上記項目のいずれか一項に記載の製剤。
(項目66)
前記凍結製剤が、解凍後、さらなる加工も培養もすることなく投与されることを特徴とする、上記項目のいずれか一項に記載の製剤。
(項目67)
前記角膜内皮細胞および/または角膜内皮様細胞を約1×105~約3×106個を含む、上記項目のいずれか一項に記載の製剤。
(項目68)
前記凍結製剤の体積は、約50μL~約600μLである、項目40~67のいずれか一項に記載の製剤。
(項目69)
前記製剤は、1回あたり約50μL~約350μL投与されることを特徴とする、上記項目のいずれか一項に記載の製剤。
(項目70)
角膜内皮細胞および/または角膜内皮様細胞とを凍結状態で含む凍結製剤を収容する容器と、該容器を凍結状態を維持しつつ収容する収容器とを含む、凍結製剤キット。
(項目71)
前記凍結製剤は、上記項目のいずれか一項に記載の製剤である、項目70に記載の凍結製剤キット。
(項目72)
上記項目のいずれか一項に記載の製剤と、該製剤を収容する容器と、該製剤を凍結状態で維持しつつ該容器を収容する収容器とを含む、凍結製剤キット。
(項目73)
容器と、該容器を収容する収容器とを含む、凍結製剤キットであって、
該容器は、上記項目のいずれか一項に記載の製剤を収容するように用いられ、該収容器は、該製剤を凍結状態で維持するように用いられる、キット。
(項目74)
ROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞とを凍結状態で含む凍結製剤を収容する容器と、該容器を凍結状態を維持しつつ収容する収容器とを含む、凍結製剤キット。
(項目75)
容器と該容器を収容する収容器とを含むキットの使用であって、
該容器は、上記項目のいずれか一項に記載の製剤を収容するように用いられ、該収容器は、該製剤を凍結状態で維持するように用いられる、使用。
(項目76)
上記項目のいずれか一項に記載の製剤の運搬および/または保存方法であって、
該製剤を、容器と該容器を収容する収容器とを含むキットの容器中に配置する工程と、
該キット中の製剤を凍結状態で維持する工程と、
を含む方法。
(項目77)
角膜内皮細胞注入療法を行う方法であって、
該細胞注入療法に適切な角膜内皮細胞および/または角膜内皮様細胞を提供する工程、
該角膜内皮細胞および/または角膜内皮様細胞を、非凍結温度から1分あたり1℃未満の速度で温度を低下する段階を少なくとも一つ含む、凍結工程、
該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持し、必要に応じて該注入療法へと運搬する工程、
該角膜内皮細胞および/または角膜内皮様細胞を解凍する工程、ならびに
該角膜内皮細胞および/または角膜内皮様細胞を被験体に投与する工程
を含む、方法。
(項目1A)
角膜内皮細胞および/または角膜内皮様細胞を保存する方法であって、該方法が、
非凍結状態の該角膜内皮細胞および/または角膜内皮様細胞を凍結する工程であって、第1の目標温度まで第1の速度で温度を低下させること、および第1の目標温度から第2の目標温度まで第2の速度で温度を低下させることを含む、凍結工程、および
必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持する工程
を含み、該第1の速度が、1分あたり1℃未満の速度であり、該第2の速度よりも遅い、方法。
(項目2A)
前記凍結工程が、前記第1の目標温度まで温度を低下させた後、前記第1の目標温度で維持することをさらに含む、上記項目のいずれか一項に記載の方法。
(項目3A)
前記第1の目標温度が、約-20℃~約-5℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目4A)
前記第1の目標温度が、約-15℃~約-10℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目5A)
前記第2の目標温度が、約-20℃以下の温度である、上記項目のいずれか一項に記載の方法。
(項目6A)
前記第2の目標温度が、約-196℃~約-80℃の範囲内の温度である、上記項目のいずれか一項に記載の方法。
(項目7A)
前記第1の速度が、1分あたり約0.5℃~約0.05℃の速度である、上記項目のいずれか一項に記載の方法。
(項目8A)
前記第1の速度が、1分あたり約0.3℃~約0.1℃の速度である、上記項目のいずれか一項に記載の方法。
(項目9A)
前記第2の速度が、1分あたり約0.5~約5℃の速度である、上記項目のいずれか一項に記載の方法。
(項目10A)
前記第2の速度が、1分あたり約1~約3℃の速度である、上記項目のいずれか一項に記載の方法。
本明細書において、「角膜内皮細胞」とは当該分野で用いられる通常の意味で用いられる。角膜とは、眼を構成する層状の組織の一つであり透明であり、最も外界に近い部分に位置する。角膜は、ヒトでは外側(体表面)から順に5層でできているとされ、外側から角膜上皮、ボーマン膜、固有層、デスメ膜(角膜内皮基底膜)、および角膜内皮で構成される。特に、特定しない限り、上皮および内皮以外の部分は「角膜実質」とまとめて称することがあり、本明細書でもそのように称する。本明細書において「HCEC」(human corneal endothelial cells)とは、ヒト角膜内皮細胞の略称である。
以下に好ましい実施形態の説明を記載するが、この実施形態は本開示の例示であり、本開示の範囲はそのような好ましい実施形態に限定されないことが理解されるべきである。当業者はまた、以下のような好ましい実施例を参考にして、本開示の範囲内にある改変、変更などを容易に行うことができることが理解されるべきである。これらの実施形態について、当業者は適宜、任意の実施形態を組み合わせ得る。
角膜内皮細胞に凍結保存において、凍結時の損傷を抑えるDMSOを10%含む保存液で凍結することにより、角膜内皮細胞を高い生存率を維持しながら保存し得る。しかしながら、DMSOの細胞に対する毒性や眼に投与した際の刺激性の懸念があったため、本発明者らは、DMSOを低減した保存液で、高い生存率を維持できる保存条件を検討したところ、-1℃/分よりも遅い低速での温度降下により、DMSO濃度を低減化した(例えば、7%未満)、あるいはDMSOを含まない凍結保存液で角膜内皮細胞の生存率が高く保たれることを見出した。
別の態様において、本開示は、角膜内皮細胞および/または角膜内皮様細胞を保存する上記方法、または角膜内皮細胞および/または角膜内皮様細胞の凍結製剤を生産する上記方法によって製造される角膜内皮細胞および/または角膜内皮様細胞の凍結製剤を提供し得る。
第2の速度は、第1の速度より速く、第1の速度から第2の速度に変化させた際に凍結が開始するような温度であれば適宜設定してよく、例えば、1分あたり約0.5~約5℃の速度、好ましくは、1分あたり約1~約3℃の速度であり得る。
さらなる態様において、本開示は、角膜内皮細胞および/または角膜内皮様細胞を保存する装置であって、該装置は該角膜内皮細胞および/または角膜内皮様細胞を収容する容器を収容する収容・保存部と、収容・保存部において収容された容器内の角膜内皮細胞および/または角膜内皮様細胞の温度を制御するように指令する温度制御部と、該収容・保存部における温度を、該温度制御部の指令に基づいて温度調節し得る、温度調節部とを含み、該温度制御部は、非凍結温度から凍結目標温度に温度を低下させる際に、1分あたり1℃未満の速度で温度を変更する段階を少なくとも1つ含むように温度制御するよう指令することができ、必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持するように指令することができる、装置を提供し得る。
さらなる態様において、本開示は、ROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞とを凍結状態で含む凍結製剤を収容する容器と、該容器を凍結状態を維持しつつ収容する収容器とを含む、凍結製剤キットを提供し得る。
さらなる態様において、本開示は、本開示の製剤の運搬および/または保存方法であって、該製剤を、容器と該容器を収容する収容器とを含むキットの容器中に配置する工程と、該キット中の製剤を凍結状態で維持する工程と、を含む方法を提供し得る。
別の態様において、本開示の方法は、非凍結温度から凍結目標温度に温度を低下させる際、第1の目標温度まで第1の速度で温度を低下させること、および第1の目標温度から第2の目標温度まで第2の速度で温度を低下させることを含み得る。前記方法は、本開示に記載の1つまたは複数の実施形態を有してもよい。
グリセリンおよびポリエチレングリコールは細胞凍結保存剤としてよく知られている成分であるが、これらの成分だけでは保存効果が低いことからアルブミンなどのタンパク質成分の添加や、10%DMSOの添加が一般に行われる。本実施例は、このような一般的条件でHCECが保存されるかどうかを確認し、さらに冷却速度を一般的に知られている-1℃/分より遅くした時に、DMSOの濃度が低い場合でも凍結保存できるのかどうかを確認することを目的とする。
・4代継代後のヒト角膜内皮細胞
・OptiMEMTM-I (Invitrogen 21585-070)
・TrypleTMSelect Enzyme (10×) (Thermo Fisher Scientific A12177-01)
・赤十字アルブミン25%静注12.5g/50mL (日本血液製剤機構)
・2.0ml Cryogenic Vials (Corning 430488)
・プログラムフリーザー (NEPAGENE PF-NP-200)
・バイセル (日本フリーザー株式会社)
・iMatrix-511 (nippi 892012)
・Bambanker hRM (日本ジェネティクス CS-11-001)
・Cryostor CS10 prefomulated with 10% DMSO (Hemacare 210102)
・Cryostor CS5 prefomulated with 5% DMSO (Hemacare 205102)
・Cryostor CS2 prefomulated with 2% DMSO (Hemacare 202102)
・CP-1 high grade (極東製薬 27207)
・Bambanker DMSO Free (日本ジェネティクス CS-09-001)
・クライオスカーレス DMSO Free (バイオベルデ CPL-A1)
・12well plate (costar 3513)
・プロテオセーブSS 遠沈管50mL (住友ベークライト MS-52550)
・ステムフル 遠沈管15mL (住友ベークライト MS-90150)
4%HSAと、10%グリセリンまたは10%ポリエチレングリコールと、10%、5%、2%または0%DMSOとを含有するOptiMEMを保存液として使用した。
1.4代継代後のヒト角膜内皮細胞を使用した。培養中の培養皿から培地を除去し、OptiMEMを添加し、洗浄した。この作業を2回繰り返した。
2.OptiMEM除去後、TrypleTMSelect Enzyme(10×)を添加し、37℃(5%CO2)で20minインキュベートした。
3.20分後培地で懸濁し、50mlステムフルに回収した。
4.300G×5min遠心した。
5.上清を除去し、OptiMEM(2%HSA)で懸濁した。
6.300G×5min遠心した。
7.5-6を再び繰り返した。
8.上清を除去し、OptiMEM(2%HSA)で懸濁し、細胞数をトリパンブルー染色によりカウントした。
9.検討する凍結保存試薬の分だけ、1.2×106個ずつ15mlステムフルに分注した。また、未凍結群(Control)として12well plateに1000cells/mm2の細胞密度で播種し、2日おきに培地交換しながら2週間培養した。
10.15mlステムフルを300G×5min遠心した。
11.回収した細胞を、凍結保存液を用いてクライオチューブに保存した。
12.プログラムフリーザーで4℃から-80℃まで、-0.5℃/minで凍結した。13.-80℃まで下がったら事前に-80℃で冷やしておいたバイセル処理容器に移動し、-80℃のフリーザー内で3日間凍結保存した。
14.3日間凍結保存後、細胞を保存したクライオチューブを37℃の水浴中で1-2分間溶かした。
15.事前に37℃に温めておいた培地で細胞を回収し、トリパンブルー染色により回収細胞数と細胞生存率を計測した。
図2は、本実施例で使用する細胞の培養形態の写真を示す。形態的な異常が無いロットであることが確認された。
(材料)
・4代継代後のヒト角膜内皮細胞
・OptiMEMTM-I (Invitrogen 21585-070)
・TrypleTMSelect Enzyme (10×) (Thermo Fisher Scientific A12177-01)
・赤十字アルブミン25%静注12.5g/50mL (日本血液製剤機構)
・2.0ml Cryogenic Vials (Corning 430488)
・プログラムフリーザー (NEPAGENE PF-NP-200)
・バイセル (日本フリーザー株式会社)
・iMatrix-511 (nippi 892012)
・Bambanker hRM (日本ジェネティクス CS-11-001)
・Cryostor CS10 prefomulated with 10% DMSO (Hemacare 210102)
・Cryostor CS5 prefomulated with 5% DMSO (Hemacare 205102)
・Cryostor CS2 prefomulated with 2% DMSO (Hemacare 202102)
・CP-1 high grade (極東製薬 27207)(10%DMSO含有)・Bambanker DMSO Free (日本ジェネティクス CS-09-001)
・クライオスカーレス DMSO Free (バイオベルデ CPL-A1)
・12well plate (costar 3513)
・プロテオセーブSS 遠沈管50mL (住友ベークライト MS-52550)
・ステムフル 遠沈管15mL (住友ベークライト MS-90150)
(方法)
1.4代継代後のヒト角膜内皮細胞を使用した。培養中の培養皿から培地を除去し、OptiMEMを添加し、洗浄した。この作業を2回繰り返した。
2.OptiMEM除去後、TrypleTMSelect Enzyme(10×)を添加し、37℃(5%CO2)で20minインキュベートした。
3.20分後培地で懸濁し、50mlステムフルに回収した。
4.300G×5min遠心した。
5.上清を除去し、OptiMEM(2%HSA)で懸濁した。
6.300G×5min遠心した。
7.5-6を再び繰り返した。
8.上清を除去し、OptiMEM(2%HSA)で懸濁し、細胞数をトリパンブルー染色によりカウントした。
9.検討する凍結保存試薬の分だけ、1.2×106個ずつ15mlステムフルに分注した。また、未凍結群(Control)として12well plateに1000cells/mm2の細胞密度で播種し、2日おきに培地交換しながら2週間培養した。
10.15mlステムフルを300G×5min遠心した。
11.各種の凍結保存試薬350μlで懸濁した。
12.各種の凍結保存試薬に終濃度100μMになるように調整したY-27632(100μl)を、11の15mlステムフルに添加して、全量450μlにした。
13.クライオチューブに450μlずつ分注した(1.2×106個/450μl)。14.プログラムフリーザーで、4℃から-80℃まで、-1℃/minもしくは-0.5℃/minもしくは-0.2℃/minで凍結させた。
15.-80℃まで下がったら事前に-80℃で冷やしておいたバイセル処理容器に移動し、-80℃フリーザー内で3日間凍結保存した。
16.3日間凍結保存後、細胞を保存したクライオチューブを37℃の水浴中で1~2分間溶した。
17.事前に37℃に温めておいた培地で細胞を回収し、トリパンブルー染色により回収細胞数と細胞生存率を計測した。
18.回収した細胞は12well plateに1000cells/mm2の細胞密度で再播種した。
19.2日おきに培地交換をしながら、2週間培養した。
20.培養7日目に位相差顕微鏡(200倍)で5視野、細胞写真を撮影し、細胞密度を算出した。
図5は、4℃から-1℃/分、-0.5℃/分または-0.2℃/分の冷却速度で凍結した細胞の融解後の生存率を比較したデータを示す。DMSOを含む凍結保存剤では-1℃/分、-0.5℃/分および-0.2℃/分のいずれの条件においても高い生存率が達成された。DMSOを含まない凍結保存剤では冷却速度と反比例する形で細胞生存率が向上していることから、冷却速度を遅くすることは細胞の生存率を上げる効果があることが示された。また、-1℃/分の冷却速度で凍結した細胞を融解して、培養器に播種すると底面に接着しない細胞が多く認められ、角膜内皮細胞の機能が低下していることが示唆される。これらのことから、-1℃/分よりも遅い冷却速度で凍結することが、角膜内皮細胞の生存率の改善および機能の維持する上で重要であることが示唆された。
(方法)
1.実施例2(1-10)と同様の方法で細胞を回収し、Cryostor CS2を用いて細胞をクライオチューブに保存する。
2.プログラムフリーザーで4℃から-80℃まで、-0.5℃/minで凍結させる。3.-80℃まで下がったら事前に-80℃で冷やしておいたバイセル処理容器に移動し、-80℃フリーザー内で3日間凍結保存する。
4.3日間凍結保存後、細胞を保存したクライオチューブを37℃の水浴中で1-2分間溶かす。
5.事前に37℃に温めておいた培地で細胞を回収し、トリパンブルー染色により回収細胞数と細胞生存率を計測する。
6.回収した細胞を、15mlステムフル4本に分注し、300G×5min遠心する。7.遠心後、上清を除去し、DMSO10%,5%,2%,0%含んだ培地を用いて1000cells/mm2の細胞密度に調整し、12well plateに再播種する。8.播種後1h,3h,6h,24hに位相差顕微鏡により細胞の写真を撮影する。
9.各時間において細胞写真を撮影後、浮いている細胞も含めて容器中の全ての細胞を回収し、トリパンブルー染色により細胞生存率を測定する。
図8は、DMSOを10%もしくは5%添加した培地で培養した細胞の位相差顕微鏡像を示す。DMSOを10%もしくは5%添加した培地で培養した細胞は、DMSOを添加しない培地で培養した細胞に比較して顕著に細胞数が低下しており、培養器の底(ラミニンコート済み)に非接着の細胞が多いことが示された。DMSOを含まない培地で培養した細胞は、接種後1時間でも大部分の細胞が接着し、3時間ではすべての細胞が接着しているのに対し、DMSO 10%では24時間まで全く細胞の接着は認められなかった。DMSO 5%でも1時間後はほとんど接着細胞が認められず、3時間後、6時間後では半数以下の細胞の接着は認められるものの、24時間後では逆に接着細胞がほとんどなくなった。図8の顕微鏡像において、白く見える細胞は非接着細胞を示し、黒く見えて非円形の細胞が接着細胞を示す。
(方法)
1.実施例2(1-10)と同様の方法で細胞を回収し、Cryostor CS10,CS5,CS2を用いてクライオチューブに各保存液あたり6本ずつ保存する。
2.プログラムフリーザーで4℃から-80℃まで、-0.5℃/minで凍結させる。3.-80℃まで下がったら事前に-80℃で冷やしておいたバイセル処理容器に移動し、-80℃フリーザー内で3日間凍結保存する。
4.3日間凍結保存後、細胞を保存したクライオチューブを37℃の水浴中で1~2分間溶かす。
5.各保存液あたり1本ずつはすぐに事前に37℃に温めておいた培地で細胞を回収し、トリパンブルー染色により細胞生存率を測定する (0h)。残りの5本ずつは、室温で30min,1h,3h,6h,24h放置させた後に同様の方法で細胞を回収し、トリパンブルー染色により細胞生存率を測定する。
6.それぞれの時間で回収した細胞は、12well plateに1000cells/mm2の細胞密度で再播種する。
7.それぞれ再播種した時間から24h培養後、位相差顕微鏡により細胞写真を撮影する。
図12は、DMSOを10%含むCryostor CS10中で凍結した細胞を0時間、30分、1時間、3時間、6時間、または24時間室温で放置した後、T25培養フラスコに再播種し、24時間後に細胞の培養状態を撮影した位相差顕微鏡像を示す。室温で6時間以上放置した場合、細胞増殖や接着能の低下が認められた。
VIXELLTMは、ドライアイスを充填することで-75℃±15℃を18日間維持できる。本実施例では、VIXELLTMを用いて角膜内皮細胞を保存・運搬を行い、その後角膜内皮細胞の注入を行う。
(凍結保存)
1.培養した角膜内皮細胞を回収し、100μMのY27632を添加したCryoStor(登録商標) CS2で1.2×106細胞/450μlの細胞密度で懸濁した。
2.プログラムフリーザーを使用して、バイアルを4℃から-0.5℃/分の速度で-80℃まで温度を低下させて凍結した。
3.保存したバイアルをBICELLTMに入れ、-80℃でディープフリーザーに一旦保存した。
4.保存されたバイアルを取り出し、ドライアイスを含むVIXELLTMに収めて5日間保存された。
直径8mmの角膜内皮細胞を剥離したモデルに対してCryostor CS2で凍結保存した培養ヒト角膜内皮細胞を医療品輸送向け保冷ボックス(VIXELLTM)で5日間保存後、前房水を灌流することなく注入することにより生体内での角膜内皮再生の動態を観察した。
図16は、保冷ボックスで5日間保存した細胞を融解した時の生存率と細胞回収率を示す。生存率は5日時点の生細胞数/総細胞数で算出した。細胞回収率は、理論上の細胞数(充填した細胞数)を100%とした時の回収率とした。
本実施例は、実施例1と同様の既知成分の凍結保存液および実施例2と同様の市販の保存液において、4℃から-0.7℃/分の冷却速度で凍結した場合の角膜内皮細胞の生存率を確認することを目的とする。
図23は、4%ヒト血清アルブミンと10%グリセリンをベース成分とした時のDMSO濃度を変えた凍結保存液で-1℃/分、-0.7℃/分、-0.5℃/分、または-0.2℃の冷却速度で凍結し、融解後の細胞の生存率を比較したグラフを示す。10%のDMSOを含む凍結保存液では、-0.5℃/分および-0.2℃の冷却速度で凍結した場合に生存率の改善傾向が認められた。また、5%のDMSOを含む凍結保存液では、-0.7℃/分、-0.5℃/分、および-0.2℃の冷却速度で凍結した場合に生存率の改善傾向が認められた。2%のDMSOを含む凍結保存液およびDMSOを含まない凍結保存液では、-0.7℃/分、-0.5℃/分、および-0.2℃の冷却速度で凍結した場合に顕著な生存率の改善が認められた。
本実施例では、ガラスバイアルでの凍結保存を行った。以下に示すように、容器に関係なく、緩慢な冷却速度で凍結することにより高い生存率で保存することができる。
実施例2(1-10)と同様の方法で細胞を回収し、以下の保存溶液および冷却速度で細胞をガラスバイアルに保存した。
・コントロール群:保存溶液:CS2+Y-27632(100μM)、凍結速度:-0.5℃/min(~-80℃)
・HSA添加群:保存溶液:CS2+Y-27632(100μM)+4%HSA、凍結速度:-0.5℃/min(~-80℃)
・速度(1)群:保存溶液:CS2+Y-27632(100μM)、凍結速度:-0.5℃/min(~-10℃),110min hold(-10℃),-1.0℃/min(~-80℃)
・速度(2)群:保存溶液:CS2+Y-27632(100μM)、凍結速度:-0.1℃/min(~-10℃),-1.0℃/min(~-80℃)
図29~31は、温度の推移を示す。サンプルの急激な温度上昇は、冷却時に見られる潜熱によるものである。-0.5℃/minで-80℃まで冷却して凍結した場合、85%を超える高い生存率で保存されることを示した。また、HSAを添加して、同じ冷却条件で保存した場合、さらに生存率が上昇し、90%を超える生存率を示した。また、緩慢な速度で-10℃まで冷却し(その後-10℃で一定時間維持してもよい)、その後-1.0℃/minの速度で冷却して保存した場合も同様に、コントロール群と比較して生存率が上昇し、90%を超える生存率を示した(図28)。すべての保存群において、細胞の形状に異常は認められなかった。
Claims (77)
- 角膜内皮細胞および/または角膜内皮様細胞を保存する方法であって、
非凍結状態の該角膜内皮細胞および/または角膜内皮様細胞を凍結する工程であって、非凍結温度から凍結目標温度に温度を変更する際に、1分あたり1℃未満の速度で温度を低下させる段階を少なくとも1つ含む、凍結工程、および
必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持する工程
を含む、方法。 - 角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持する工程を含む、請求項1に記載の方法。
- 前記凍結状態で維持する工程は、凍結維持温度で維持することを含む、請求項1または2に記載の方法。
- 前記凍結維持温度が、約-80℃~約-10℃の範囲内の温度である、請求項3に記載の方法。
- 前記凍結維持温度が、約-196℃~約-10℃の範囲内の温度である、請求項3に記載の方法。
- 前記凍結維持温度が、約-30℃以下の温度である、請求項3に記載の方法。
- 前記角膜内皮細胞および/または角膜内皮様細胞が、非凍結温度から1分あたり約0.1℃~約0.9℃の速度で温度を低下される、請求項1~6のいずれか一項に記載の方法。
- 前記角膜内皮細胞および/または角膜内皮様細胞が、非凍結温度から1分あたり約0.2℃~約0.8℃の速度で温度を低下される、請求項1~6のいずれか一項に記載の方法。
- 前記角膜内皮細胞および/または角膜内皮様細胞が、非凍結温度から1分あたり約0.7℃以下の速度で温度を低下される、請求項1~6のいずれか一項に記載の方法。
- 前記角膜内皮細胞および/または角膜内皮様細胞が、非凍結温度から1分あたり約0.2℃~約0.7℃の速度で温度を低下される、請求項1~6のいずれか一項に記載の方法。
- 前記非凍結温度が、約0℃~約42℃の範囲内の温度である、請求項1~10のいずれか一項に記載の方法。
- 前記非凍結温度が、約0℃~約37℃の範囲内の温度である、請求項1~10のいずれか一項に記載の方法。
- 前記非凍結温度が、約4℃~約23℃の範囲内の温度である、請求項1~10のいずれか一項に記載の方法。
- 前記凍結工程は、約-20℃±10℃の少なくとも一部の温度範囲において、1分あたり1℃未満の速度で温度を低下させる段階を少なくとも1つ含む、請求項1~13のいずれか一項に記載の方法。
- 前記凍結工程は、約-20℃±10℃の温度範囲に一定時間以上維持する段階を少なくとも1つ含む、請求項1~13のいずれか一項に記載の方法。
- 前記角膜内皮細胞および/または角膜内皮様細胞が、約7%未満のDMSOを含む保存液中で保存される、請求項1~15のいずれか一項に記載の方法。
- 前記角膜内皮細胞および/または角膜内皮様細胞が、約5%以下のDMSOを含む保存液中で保存される、請求項1~15のいずれか一項に記載の方法。
- 前記角膜内皮細胞および/または角膜内皮様細胞が、約2%以下のDMSOを含む保存液中で保存される、請求項1~15のいずれか一項に記載の方法。
- 前記角膜内皮細胞および/または角膜内皮様細胞が、DMSOを含まない保存液中で保存される、請求項1~15のいずれか一項に記載の方法。
- 前記凍結工程は、角膜内皮細胞および/または角膜内皮様細胞がROCK阻害剤の存在下で凍結されていることを含む、請求項1~19のいずれか一項に記載の方法。
- 前記凍結工程が、第1の目標温度まで第1の速度で温度を低下させること、および第1の目標温度から第2の目標温度まで第2の速度で温度を低下させることを含み、該第1の速度が、1分あたり1℃未満の速度であり、該第2の速度よりも遅い、請求項1に記載の方法。
- 前記凍結工程が、前記第1の目標温度まで温度を低下させた後、前記第1の目標温度で維持することをさらに含む、請求項21に記載の方法。
- 前記第1の目標温度が、約-20℃~約-5℃の範囲内の温度である、請求項21または22に記載の方法。
- 前記第1の目標温度が、約-15℃~約-10℃の範囲内の温度である、請求項21または22に記載の方法。
- 前記第2の目標温度が、約-20℃以下の温度である、請求項21~24のいずれか一項に記載の方法。
- 前記第2の目標温度が、約-196℃~約-80℃の範囲内の温度である、請求項21~24のいずれか一項に記載の方法。
- 前記第1の速度が、1分あたり約0.5℃~約0.05℃の速度である、請求項21~26のいずれか一項に記載の方法。
- 前記第1の速度が、1分あたり約0.3℃~約0.1℃の速度である、請求項21~26のいずれか一項に記載の方法。
- 前記第2の速度が、1分あたり約0.5~約5℃の速度である、請求項21~28のいずれか一項に記載の方法。
- 前記第2の速度が、1分あたり約1~約3℃の速度である、請求項21~28のいずれか一項に記載の方法。
- 角膜内皮細胞および/または角膜内皮様細胞の凍結製剤を生産する方法であって、
非凍結状態の該角膜内皮細胞および/または角膜内皮様細胞を必要に応じて薬学的に受容可能な成分と混合し、凍結して凍結製剤を生産する工程であって、非凍結温度から凍結目標温度に温度を変更する際に、1分あたり1℃未満の速度で温度を低下させる段階を少なくとも1つ含む、凍結工程、および
必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞の該凍結製剤を凍結状態で維持する工程
を含む、方法。 - 請求項2~30のいずれかまたは複数の項に記載の方法に記載される1または複数の特徴をさらに含む、請求項31に記載の方法。
- 請求項1~32のいずれか一項に記載の方法によって製造される角膜内皮細胞および/または角膜内皮様細胞の凍結製剤。
- 前記角膜内皮細胞および/または角膜内皮様細胞を約1×105~約3×106個を含む、請求項33に記載の凍結製剤。
- 前記凍結製剤の体積は、約50μL~約600μLである、請求項33または34に記載の凍結製剤。
- 前記凍結製剤は、1回あたり約50μL~約350μL投与されることを特徴とする、請求項33~35のいずれか一項に記載の凍結製剤。
- 角膜内皮細胞および/または角膜内皮様細胞を保存する装置であって、該装置は
該角膜内皮細胞および/または角膜内皮様細胞を収容する容器を収容する収容・保存部と、
収容・保存部において収容された容器内の角膜内皮細胞および/または角膜内皮様細胞の温度を制御するように指令する温度制御部と
該収容・保存部における温度を、該温度制御部の指令に基づいて温度調節し得る、温度調節部と
を含み、
該温度制御部は、非凍結温度から凍結目標温度に温度を低下させる際に、1分あたり1℃未満の速度で温度を変更する段階を少なくとも1つ含むように温度制御するよう指令することができ、必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持するように指令することができる、装置。 - 装置において角膜内皮細胞および/または角膜内皮様細胞を保存することができるようにコンピュータに実装させる方法をコードするプログラムであって、該装置は該角膜内皮細胞および/または角膜内皮様細胞を収容する容器を収容する収容・保存部と、収容・保存部において収容された容器内の角膜内皮細胞および/または角膜内皮様細胞の温度を制御するように指令する温度制御部と、該収容・保存部における温度を、該温度制御部の指令に基づいて温度調節し得る、温度調節部とを含み、
該プログラムは、該温度制御部に対して、非凍結温度から凍結目標温度に温度を低下させる際に、1分あたり1℃未満の速度で温度を変更する段階を少なくとも1つ含むように温度制御させ、必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持させる、プログラム。 - 装置において角膜内皮細胞および/または角膜内皮様細胞を保存することができるようにコンピュータに実装させる方法をコードするプログラムを格納した記録媒体であって、該装置は該角膜内皮細胞および/または角膜内皮様細胞を収容する容器を収容する収容・保存部と、収容・保存部において収容された容器内の角膜内皮細胞および/または角膜内皮様細胞の温度を制御するように指令する温度制御部と、該収容・保存部における温度を、該温度制御部の指令に基づいて温度調節し得る、温度調節部とを含み、
該プログラムは、該温度制御部に対して、非凍結温度から凍結目標温度に温度を低下させる際に、1分あたり1℃未満の速度で温度を変更する段階を少なくとも1つ含むように温度制御させ、必要に応じて、該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持させる、記録媒体。 - 7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞とを含む、凍結製剤。
- 7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞とを含む、解凍後眼に直接投与可能な凍結製剤。
- 7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞とを緩慢凍結状態で凍結された状態で含む、凍結製剤。
- 7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞と生理食塩水の成分とを凍結状態で含む凍結製剤。
- 7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞と培地成分とを凍結状態で含む凍結製剤。
- 7%未満のDMSOと角膜内皮細胞および/または角膜内皮様細胞とを含む解凍後長期安定性凍結細胞製剤。
- 約5%以下のDMSOを含む、請求項40~45のいずれか一項に記載の凍結製剤。
- 約2%以下のDMSOを含む、請求項40~45のいずれか一項に記載の凍結製剤。
- DMSOを含まない、請求項40~45のいずれか一項に記載の凍結製剤。
- ROCK阻害剤をさらに含む、請求項40~48のいずれか一項に記載の凍結製剤。
- 前記ROCK阻害剤が、Y-27632である、請求項49に記載の凍結製剤。
- ROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞とを凍結状態で含む凍結製剤。
- ROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞と生理食塩水の成分とを凍結状態で含む凍結製剤。
- ROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞と培地成分とを凍結状態で含む凍結製剤。
- 解凍後長期安定性凍結細胞製剤であって、該製剤は、角膜内皮細胞および/または角膜内皮様細胞とROCK阻害剤とを含む、製剤。
- 前記角膜内皮細胞および/または角膜内皮様細胞の生存率が、解凍後、室温で少なくとも6時間少なくとも80%の生存率である、請求項54に記載の製剤。
- 解凍後投与された角膜内皮細胞および/または角膜内皮様細胞の生着および生体内における生存が阻害されない凍結製剤であって、該製剤は、角膜内皮細胞および/または角膜内皮様細胞とROCK阻害剤とを緩慢凍結状態で凍結された状態で含む、凍結製剤。
- 7%未満のDMSOとROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞とを緩慢凍結状態で凍結された状態で含む、凍結製剤。
- 前記ROCK阻害剤が、Y-27632である、請求項50~57のいずれか一項に記載の製剤。
- 約7%未満のDMSOを含む、請求項50~56のいずれか一項に記載の製剤。
- 約5%以下のDMSOを含む、請求項50~56のいずれか一項に記載の製剤。
- 約2%以下のDMSOを含む、請求項50~56のいずれか一項に記載の製剤。
- DMSOを含まない、請求項50~56のいずれか一項に記載の製剤。
- 前記製剤は、緩慢凍結状態で凍結された状態で前記細胞を含む、請求項30~52のいずれか一項に記載の製剤。
- 前記製剤が、非凍結温度から1分あたり1℃未満の速度で温度を低下させて凍結されたものである、請求項30~53のいずれか一項に記載の製剤。
- 前記角膜内皮細胞および/または角膜内皮様細胞が、細胞注入療法に使用されることを特徴とする、請求項40~64のいずれか一項に記載の製剤。
- 前記凍結製剤が、解凍後、さらなる加工も培養もすることなく投与されることを特徴とする、請求項40~65のいずれか一項に記載の製剤。
- 前記角膜内皮細胞および/または角膜内皮様細胞を約1×105~約3×106個を含む、請求項40~66のいずれか一項に記載の製剤。
- 前記凍結製剤の体積は、約50μL~約600μLである、請求項40~67のいずれか一項に記載の製剤。
- 前記製剤は、1回あたり約50μL~約350μL投与されることを特徴とする、請求項40~68のいずれか一項に記載の製剤。
- 角膜内皮細胞および/または角膜内皮様細胞とを凍結状態で含む凍結製剤を収容する容器と、該容器を凍結状態を維持しつつ収容する収容器とを含む、凍結製剤キット。
- 前記凍結製剤は、請求項30~59のいずれか一項に記載の製剤である、請求項70に記載の凍結製剤キット。
- 請求項40~69のいずれか一項に記載の製剤と、該製剤を収容する容器と、該製剤を凍結状態で維持しつつ該容器を収容する収容器とを含む、凍結製剤キット。
- 容器と、該容器を収容する収容器とを含む、凍結製剤キットであって、
該容器は、請求項40~69のいずれか一項に記載の製剤を収容するように用いられ、該収容器は、該製剤を凍結状態で維持するように用いられる、キット。 - ROCK阻害剤と角膜内皮細胞および/または角膜内皮様細胞とを凍結状態で含む凍結製剤を収容する容器と、該容器を凍結状態を維持しつつ収容する収容器とを含む、凍結製剤キット。
- 容器と該容器を収容する収容器とを含むキットの使用であって、
該容器は、請求項40~69のいずれか一項に記載の製剤を収容するように用いられ、該収容器は、該製剤を凍結状態で維持するように用いられる、使用。 - 請求項40~69のいずれか一項に記載の製剤の運搬および/または保存方法であって、
該製剤を、容器と該容器を収容する収容器とを含むキットの容器中に配置する工程と、
該キット中の製剤を凍結状態で維持する工程と、
を含む方法。 - 角膜内皮細胞注入療法を行う方法であって、
該細胞注入療法に適切な角膜内皮細胞および/または角膜内皮様細胞を提供する工程、
該角膜内皮細胞および/または角膜内皮様細胞を、非凍結温度から1分あたり1℃未満の速度で温度を低下する段階を少なくとも一つ含む、凍結工程、
該角膜内皮細胞および/または角膜内皮様細胞を凍結状態で維持し、必要に応じて該注入療法へと運搬する工程、
該角膜内皮細胞および/または角膜内皮様細胞を解凍する工程、ならびに
該角膜内皮細胞および/または角膜内皮様細胞を被験体に投与する工程
を含む、方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022385051A AU2022385051A1 (en) | 2021-11-11 | 2022-11-10 | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
CA3238227A CA3238227A1 (en) | 2021-11-11 | 2022-11-10 | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
JP2023559903A JPWO2023085369A1 (ja) | 2021-11-11 | 2022-11-10 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-184246 | 2021-11-11 | ||
JP2021184246 | 2021-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023085369A1 true WO2023085369A1 (ja) | 2023-05-19 |
Family
ID=86335877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/041960 WO2023085369A1 (ja) | 2021-11-11 | 2022-11-10 | 角膜内皮細胞の凍結保存製剤およびその製造法 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPWO2023085369A1 (ja) |
AU (1) | AU2022385051A1 (ja) |
CA (1) | CA3238227A1 (ja) |
WO (1) | WO2023085369A1 (ja) |
Citations (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678783A (en) | 1983-11-04 | 1987-07-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Substituted isoquinolinesulfonyl compounds |
WO1995028387A1 (fr) | 1994-04-18 | 1995-10-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose benzamide et utilisation medicale dudit compose |
WO1999020620A1 (fr) | 1997-10-22 | 1999-04-29 | Nippon Shinyaku Co Ltd | Derive d'isoquinoleine et medicament |
WO1999061403A1 (fr) | 1998-05-25 | 1999-12-02 | Santen Pharmaceutical Co., Ltd. | Nouveaux derives vinylbenzene |
WO2002076977A2 (en) | 2001-03-23 | 2002-10-03 | Bayer Corporation | Rho-kinase inhibitors |
WO2002076976A2 (en) | 2001-03-23 | 2002-10-03 | Bayer Corporation | Rho-kinase inhibitors |
WO2002083175A1 (fr) | 2001-04-11 | 2002-10-24 | Senju Pharmaceutical Co., Ltd. | Agents ameliorant la fonction visuelle |
WO2002100833A1 (fr) | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
JP3421217B2 (ja) | 1995-11-20 | 2003-06-30 | 麒麟麦酒株式会社 | Rho標的タンパク質Rhoキナーゼ |
WO2003059913A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
WO2003062227A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
WO2004009555A1 (ja) | 2002-07-22 | 2004-01-29 | Asahi Kasei Pharma Corporation | 5−置換イソキノリン誘導体 |
WO2004022541A1 (en) | 2002-09-03 | 2004-03-18 | Universite De Montreal | 1,4-substituted cyclohexane derivatives |
WO2004108724A1 (ja) | 2003-06-06 | 2004-12-16 | Asahi Kasei Pharma Corporation | 3環系化合物 |
WO2005003101A2 (en) | 2003-07-02 | 2005-01-13 | Biofocus Discovery Limited | Pyrazine and pyridine derivatives as rho kinase inhibitors |
WO2005034866A2 (en) | 2003-10-06 | 2005-04-21 | Glaxo Group Limited | Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors |
WO2005035501A1 (ja) | 2003-10-15 | 2005-04-21 | Ube Industries, Ltd. | 新規オレフィン誘導体 |
WO2005035503A1 (ja) | 2003-10-15 | 2005-04-21 | Ube Industries, Ltd. | 新規イソキノリン誘導体 |
WO2005035506A1 (ja) | 2003-10-15 | 2005-04-21 | Ube Industries, Ltd. | 新規インダゾール誘導体 |
WO2005037198A2 (en) | 2003-10-06 | 2005-04-28 | Glaxo Group Limited | Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors |
WO2005037197A2 (en) | 2003-10-06 | 2005-04-28 | Glaxo Group Limited | Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors |
WO2005039564A1 (en) | 2003-10-02 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | Phthalimide compounds useful as protein kinase inhibitors |
WO2005080394A1 (en) | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
WO2005097790A1 (de) | 2004-04-08 | 2005-10-20 | Bayer Healthcare Ag | Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer |
WO2005103050A2 (en) | 2004-04-02 | 2005-11-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
WO2006057270A1 (ja) | 2004-11-26 | 2006-06-01 | Asahi Kasei Pharma Corporation | 含窒素3環化合物 |
WO2007026664A1 (ja) | 2005-08-30 | 2007-03-08 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
WO2008036540A2 (en) | 2006-09-20 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
WO2008077550A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
WO2010104851A1 (en) | 2009-03-09 | 2010-09-16 | Surface Logix, Inc. | Rho kinase inhibitors |
WO2011107608A1 (en) | 2010-03-02 | 2011-09-09 | Amakem Nv | Heterocyclic amides as rock inhibitors |
WO2012146724A2 (en) | 2011-04-29 | 2012-11-01 | Amakem Nv | Novel rock inhibitors |
WO2013030366A1 (en) | 2011-08-31 | 2013-03-07 | Amakem Nv | Novel soft rock inhibitors |
WO2014055996A2 (en) | 2012-10-05 | 2014-04-10 | Kadmon Corporation, Llc | Rho kinase inhibitors |
WO2014068035A1 (en) | 2012-10-31 | 2014-05-08 | Amakem Nv | Novel rock inhibitors |
WO2014113620A2 (en) | 2013-01-18 | 2014-07-24 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as rock inhibitors |
WO2014142038A1 (ja) * | 2013-03-11 | 2014-09-18 | Jcrファーマ株式会社 | ヒト角膜上皮シートの製造法 |
WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
WO2015002915A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyri do-carboxam i d e derivatives as rock inhibitors |
WO2015054317A1 (en) | 2013-10-07 | 2015-04-16 | Kadmon Corporation, Llc | Rho kinase inhibitors |
WO2015165341A1 (zh) | 2014-04-28 | 2015-11-05 | 南京明德新药研发股份有限公司 | 作为rho激酶抑制剂的异喹啉磺酰衍生物 |
WO2016028971A1 (en) | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
WO2016112236A1 (en) | 2015-01-09 | 2016-07-14 | Bristol-Myers Squibb Company | Cyclic ureas as inhibitors of rock |
WO2017123860A1 (en) | 2016-01-13 | 2017-07-20 | Bristol-Myers Squibb Company | Spiroheptane salicylamides and related compounds as inhibitors of rock |
WO2017205709A1 (en) | 2016-05-27 | 2017-11-30 | Bristol-Myers Squibb Company | Triazolones and tetrazolones as inhibitors of rock |
WO2018009625A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Spirolactams as inhibitors of rock |
WO2018009622A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors |
WO2018009627A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
WO2018102325A1 (en) | 2016-11-30 | 2018-06-07 | Bristol-Myers Squibb Company | Tricyclic rho kinase inhibitors |
WO2018118109A1 (en) | 2016-12-21 | 2018-06-28 | BioAxone BioSciences, Inc. | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
WO2018115383A1 (en) | 2016-12-21 | 2018-06-28 | Chiesi Farmaceutici S.P.A. | Bicyclic dihydropyrimidine-carboxamide derivatives as rho-kinase inhibitors |
WO2018138293A1 (en) | 2017-01-30 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
JP2018533377A (ja) * | 2015-11-16 | 2018-11-15 | アクロン・バイオテクノロジー・リミテッド・ライアビリティ・カンパニーAkron Biotechnology, LLC | 凍結保存組成物およびその使用方法 |
WO2019014300A1 (en) | 2017-07-12 | 2019-01-17 | Bristol-Myers Squibb Company | PHENYLACETAMIDES AS ROCK INHIBITORS |
WO2019014304A1 (en) | 2017-07-12 | 2019-01-17 | Bristol-Myers Squibb Company | SPIROHEPTANYL HYDANTOIDS AS ROCK INHIBITORS |
JP2019024325A (ja) * | 2017-07-25 | 2019-02-21 | 国立大学法人京都大学 | ヒト多能性幹細胞由来心筋細胞の凍結方法 |
WO2019089868A1 (en) | 2017-11-03 | 2019-05-09 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
WO2020045642A1 (ja) * | 2018-08-31 | 2020-03-05 | 学校法人同志社 | 眼細胞を保存または培養するための組成物および方法 |
WO2020166711A1 (ja) * | 2019-02-15 | 2020-08-20 | イビデン株式会社 | 凍結保存液 |
JP2020162533A (ja) * | 2019-03-29 | 2020-10-08 | 群栄化学工業株式会社 | 細胞凍結保存方法、細胞凍結保存用組成物、および細胞凍結保存用培地 |
JP2020202772A (ja) * | 2019-06-17 | 2020-12-24 | 三菱製紙株式会社 | 凍結保存用治具 |
JP2021184246A (ja) | 2020-05-22 | 2021-12-02 | 富士通株式会社 | 命令変換支援プログラム、命令変換支援方法および情報処理装置 |
-
2022
- 2022-11-10 WO PCT/JP2022/041960 patent/WO2023085369A1/ja active Application Filing
- 2022-11-10 CA CA3238227A patent/CA3238227A1/en active Pending
- 2022-11-10 AU AU2022385051A patent/AU2022385051A1/en active Pending
- 2022-11-10 JP JP2023559903A patent/JPWO2023085369A1/ja active Pending
Patent Citations (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678783A (en) | 1983-11-04 | 1987-07-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Substituted isoquinolinesulfonyl compounds |
US4678783B1 (en) | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
WO1995028387A1 (fr) | 1994-04-18 | 1995-10-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose benzamide et utilisation medicale dudit compose |
JP3421217B2 (ja) | 1995-11-20 | 2003-06-30 | 麒麟麦酒株式会社 | Rho標的タンパク質Rhoキナーゼ |
WO1999020620A1 (fr) | 1997-10-22 | 1999-04-29 | Nippon Shinyaku Co Ltd | Derive d'isoquinoleine et medicament |
WO1999061403A1 (fr) | 1998-05-25 | 1999-12-02 | Santen Pharmaceutical Co., Ltd. | Nouveaux derives vinylbenzene |
WO2002076977A2 (en) | 2001-03-23 | 2002-10-03 | Bayer Corporation | Rho-kinase inhibitors |
WO2002076976A2 (en) | 2001-03-23 | 2002-10-03 | Bayer Corporation | Rho-kinase inhibitors |
WO2002083175A1 (fr) | 2001-04-11 | 2002-10-24 | Senju Pharmaceutical Co., Ltd. | Agents ameliorant la fonction visuelle |
WO2002100833A1 (fr) | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
WO2003059913A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
WO2003062227A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
WO2004009555A1 (ja) | 2002-07-22 | 2004-01-29 | Asahi Kasei Pharma Corporation | 5−置換イソキノリン誘導体 |
WO2004022541A1 (en) | 2002-09-03 | 2004-03-18 | Universite De Montreal | 1,4-substituted cyclohexane derivatives |
WO2004108724A1 (ja) | 2003-06-06 | 2004-12-16 | Asahi Kasei Pharma Corporation | 3環系化合物 |
WO2005003101A2 (en) | 2003-07-02 | 2005-01-13 | Biofocus Discovery Limited | Pyrazine and pyridine derivatives as rho kinase inhibitors |
WO2005039564A1 (en) | 2003-10-02 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | Phthalimide compounds useful as protein kinase inhibitors |
WO2005034866A2 (en) | 2003-10-06 | 2005-04-21 | Glaxo Group Limited | Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors |
WO2005037198A2 (en) | 2003-10-06 | 2005-04-28 | Glaxo Group Limited | Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors |
WO2005037197A2 (en) | 2003-10-06 | 2005-04-28 | Glaxo Group Limited | Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors |
WO2005035501A1 (ja) | 2003-10-15 | 2005-04-21 | Ube Industries, Ltd. | 新規オレフィン誘導体 |
WO2005035503A1 (ja) | 2003-10-15 | 2005-04-21 | Ube Industries, Ltd. | 新規イソキノリン誘導体 |
WO2005035506A1 (ja) | 2003-10-15 | 2005-04-21 | Ube Industries, Ltd. | 新規インダゾール誘導体 |
WO2005080394A1 (en) | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
WO2005103050A2 (en) | 2004-04-02 | 2005-11-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
WO2005097790A1 (de) | 2004-04-08 | 2005-10-20 | Bayer Healthcare Ag | Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer |
WO2006057270A1 (ja) | 2004-11-26 | 2006-06-01 | Asahi Kasei Pharma Corporation | 含窒素3環化合物 |
WO2007026664A1 (ja) | 2005-08-30 | 2007-03-08 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
WO2008036540A2 (en) | 2006-09-20 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
WO2008077550A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
WO2010104851A1 (en) | 2009-03-09 | 2010-09-16 | Surface Logix, Inc. | Rho kinase inhibitors |
WO2011107608A1 (en) | 2010-03-02 | 2011-09-09 | Amakem Nv | Heterocyclic amides as rock inhibitors |
WO2012146724A2 (en) | 2011-04-29 | 2012-11-01 | Amakem Nv | Novel rock inhibitors |
WO2013030366A1 (en) | 2011-08-31 | 2013-03-07 | Amakem Nv | Novel soft rock inhibitors |
WO2014055996A2 (en) | 2012-10-05 | 2014-04-10 | Kadmon Corporation, Llc | Rho kinase inhibitors |
WO2014068035A1 (en) | 2012-10-31 | 2014-05-08 | Amakem Nv | Novel rock inhibitors |
WO2014113620A2 (en) | 2013-01-18 | 2014-07-24 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as rock inhibitors |
WO2014142038A1 (ja) * | 2013-03-11 | 2014-09-18 | Jcrファーマ株式会社 | ヒト角膜上皮シートの製造法 |
WO2015002915A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyri do-carboxam i d e derivatives as rock inhibitors |
WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
WO2015054317A1 (en) | 2013-10-07 | 2015-04-16 | Kadmon Corporation, Llc | Rho kinase inhibitors |
WO2015165341A1 (zh) | 2014-04-28 | 2015-11-05 | 南京明德新药研发股份有限公司 | 作为rho激酶抑制剂的异喹啉磺酰衍生物 |
WO2016028971A1 (en) | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
WO2016112236A1 (en) | 2015-01-09 | 2016-07-14 | Bristol-Myers Squibb Company | Cyclic ureas as inhibitors of rock |
JP2018533377A (ja) * | 2015-11-16 | 2018-11-15 | アクロン・バイオテクノロジー・リミテッド・ライアビリティ・カンパニーAkron Biotechnology, LLC | 凍結保存組成物およびその使用方法 |
WO2017123860A1 (en) | 2016-01-13 | 2017-07-20 | Bristol-Myers Squibb Company | Spiroheptane salicylamides and related compounds as inhibitors of rock |
WO2017205709A1 (en) | 2016-05-27 | 2017-11-30 | Bristol-Myers Squibb Company | Triazolones and tetrazolones as inhibitors of rock |
WO2018009622A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors |
WO2018009627A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
WO2018009625A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Spirolactams as inhibitors of rock |
WO2018102325A1 (en) | 2016-11-30 | 2018-06-07 | Bristol-Myers Squibb Company | Tricyclic rho kinase inhibitors |
WO2018118109A1 (en) | 2016-12-21 | 2018-06-28 | BioAxone BioSciences, Inc. | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
WO2018115383A1 (en) | 2016-12-21 | 2018-06-28 | Chiesi Farmaceutici S.P.A. | Bicyclic dihydropyrimidine-carboxamide derivatives as rho-kinase inhibitors |
WO2018138293A1 (en) | 2017-01-30 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
WO2019014300A1 (en) | 2017-07-12 | 2019-01-17 | Bristol-Myers Squibb Company | PHENYLACETAMIDES AS ROCK INHIBITORS |
WO2019014304A1 (en) | 2017-07-12 | 2019-01-17 | Bristol-Myers Squibb Company | SPIROHEPTANYL HYDANTOIDS AS ROCK INHIBITORS |
JP2019024325A (ja) * | 2017-07-25 | 2019-02-21 | 国立大学法人京都大学 | ヒト多能性幹細胞由来心筋細胞の凍結方法 |
WO2019089868A1 (en) | 2017-11-03 | 2019-05-09 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
WO2020045642A1 (ja) * | 2018-08-31 | 2020-03-05 | 学校法人同志社 | 眼細胞を保存または培養するための組成物および方法 |
WO2020166711A1 (ja) * | 2019-02-15 | 2020-08-20 | イビデン株式会社 | 凍結保存液 |
JP2020162533A (ja) * | 2019-03-29 | 2020-10-08 | 群栄化学工業株式会社 | 細胞凍結保存方法、細胞凍結保存用組成物、および細胞凍結保存用培地 |
JP2020202772A (ja) * | 2019-06-17 | 2020-12-24 | 三菱製紙株式会社 | 凍結保存用治具 |
JP2021184246A (ja) | 2020-05-22 | 2021-12-02 | 富士通株式会社 | 命令変換支援プログラム、命令変換支援方法および情報処理装置 |
Non-Patent Citations (8)
Title |
---|
ALI ET AL., INVEST OPHTHALMOL VIS SCI., vol. 59, no. 6, 1 May 2018 (2018-05-01), pages 2437 - 2444 |
FUKUTA ET AL., PLOS ONE., vol. 9, no. 12, 2 December 2014 (2014-12-02), pages e112291 |
HAYASHI ET AL., NATURE, vol. 531, no. 7594, 17 March 2016 (2016-03-17), pages 376 - 80 |
MCCABE ET AL., PLOS ONE., vol. 10, no. 12, 21 December 2015 (2015-12-21), pages e0145266 |
MIMURA ET AL., EXP EYE RES, vol. 76, no. 6, June 2003 (2003-06-01), pages 745 - 51 |
MIMURA ET AL., EXP EYE RES, vol. 80, no. 2, February 2005 (2005-02-01), pages 149 - 57 |
OKUMURA NAOKI, KAGAMI TAKATO, WATANABE KYOKO, KADOYA SAORI, SATO MASAKAZU, KOIZUMI NORIKO: "Feasibility of a cryopreservation of cultured human corneal endothelial cells", PLOS ONE, vol. 14, no. 6, 21 June 2019 (2019-06-21), pages e0218431, XP093066079, DOI: 10.1371/journal.pone.0218431 * |
PATEL ET AL., INVEST OPHTHALMOL VIS SCI., vol. 50, no. 5, May 2009 (2009-05-01), pages 2123 - 31 |
Also Published As
Publication number | Publication date |
---|---|
AU2022385051A1 (en) | 2024-06-20 |
CA3238227A1 (en) | 2023-05-19 |
JPWO2023085369A1 (ja) | 2023-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vogel et al. | The 24‐hour normothermic machine perfusion of discarded human liver grafts | |
JP6336392B2 (ja) | 移植のための臓器又は組織の長期維持方法 | |
Gurruchaga et al. | Advances in the slow freezing cryopreservation of microencapsulated cells | |
US11246308B2 (en) | Ice-free preservation of large volume tissue samples for viable, functional tissue banking | |
JP2000344602A (ja) | 動物の細胞または臓器の保存剤およびその保存方法。 | |
CN108207930A (zh) | 一种鸡尾酒式冷冻保护剂及其应用 | |
JP5796290B2 (ja) | 膵島組織保存溶液及びそれを用いる方法 | |
KR101407355B1 (ko) | 식물 유래의 재조합 인간 혈청 알부민, 지질 및 식물 단백질 가수분해물을 유효성분으로 포함하는 줄기세포 또는 일차배양세포의 동결보존용 조성물 | |
Stoll et al. | Membrane stability during biopreservation of blood cells | |
Bonaccorsi-Riani et al. | Machine perfusion: cold versus warm, versus neither. update on clinical trials | |
US20190275088A1 (en) | Preservative solution for live cells or composition containing live cells | |
US20220354108A1 (en) | Preservation methods using trehalose with other cryoprotectants being absent from the cryopreservation protocol | |
JP2021509121A (ja) | 凍結保存用組成物およびその使用方法 | |
WO2020045642A1 (ja) | 眼細胞を保存または培養するための組成物および方法 | |
JP2003267801A (ja) | 保存剤用組成物及び該組成物を含有する動物の細胞または臓器の保存剤 | |
JP2009219376A (ja) | 医療用細胞の保護用液 | |
WO2023085369A1 (ja) | 角膜内皮細胞の凍結保存製剤およびその製造法 | |
CA3161472A1 (en) | Ice-free vitrification and nano-warming of large tissue samples | |
JP6329468B2 (ja) | 線維芽細胞のガラス化凍結保存方法 | |
KR20240110954A (ko) | 각막 내피 세포의 냉동보존 제제 및 상기 냉동보존 제제를 생산하기 위한 방법 | |
CN118434843A (zh) | 角膜内皮细胞的冷冻保存制剂及其制造方法 | |
WO2015026307A1 (en) | Boron added cell cryopreservation medium | |
Magalhaes et al. | The use of vitrification to preserve primary rat hepatocyte monolayer on collagen-coated poly (ethylene-terephthalate) surfaces for a hybrid liver support system | |
RU2777097C1 (ru) | Способ рекондиционирования донорского сердца | |
WO2022025240A1 (ja) | 角膜内皮細胞を保存するための方法および容器 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22892867 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023559903 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3238227 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022385051 Country of ref document: AU Ref document number: AU2022385051 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020247019137 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022892867 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022385051 Country of ref document: AU Date of ref document: 20221110 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022892867 Country of ref document: EP Effective date: 20240611 |